1	<b>Reversing Immunosenescence with Senolytics to Enhance Tumor</b>
2	Immunotherapy
3	Niu Liu <sup>1,2,3#</sup> , Jiaying Wu <sup>1,2#</sup> , Enze Deng <sup>4,5#</sup> , Jianglong Zhong <sup>1,2#</sup> , Bin Wei <sup>1,2#</sup> , Tingting Cai <sup>1,2#</sup> ,
4	Xiaohui Duan <sup>6</sup> , Sha Fu <sup>7</sup> , David O. Osei-Hwedieh <sup>8</sup> , Ou Sha <sup>9</sup> , Yunsheng Chen <sup>1,2,3</sup> , Xiaobin Lv <sup>10</sup> ,
5	Yingying Zhu <sup>11</sup> , Lizao Zhang <sup>1,2</sup> , Hsinyu Lin <sup>1,2</sup> , Qunxing Li <sup>1,2</sup> , Peichia Lu <sup>1,2</sup> , Jiahao Miao <sup>1,2,3</sup> ,
6	Teppei Yamada <sup>12</sup> , Lei Cai <sup>13</sup> , Hongwei Du <sup>14</sup> , Sylvan C. Baca <sup>8</sup> , Qingpei Huang <sup>4</sup> , Soldano Ferrone <sup>†</sup>
7	, Xinhui Wang <sup>15*</sup> , Fang Xu <sup>3,16,17*</sup> , Xiaoying Fan <sup>4,18*</sup> , Song Fan <sup>1,2*</sup>
8	
9	Affiliations:
10	<sup>1</sup> Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene
11	Regulation, Sun Yat-sen Memorial Hospital; Guangzhou, 510120, China.
12	<sup>2</sup> Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-
13	sen University; Guangzhou, 510120, China.
14	<sup>3</sup> Interdisciplinary Center for Brain Information, Brain Cognition and Brain Disease Institute,
15	Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences; Shenzhen,
16	518055, China.
17	<sup>4</sup> Guangzhou National Laboratory, Guangzhou International Bio Island; Guangzhou, 510005,
18	China.
19	<sup>5</sup> MOE Key Laboratory of Gene Function and Regulation, Guangdong Province Key
20	Laboratory of Pharmaceutical Functional Genes, State Key Laboratory of Biocontrol, School
21	of Life Sciences, Sun Yat-sen University; Guangzhou, 510275, China.

- <sup>6</sup>Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University;
   Guangzhou, 510120, China.
- <sup>7</sup>Department of Cellular & Molecular Diagnostics Center, Sun Yat-Sen Memorial Hospital,
- 25 Sun Yat-Sen University; Guangzhou, 510120, China.
- <sup>8</sup>Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, 02215, USA.
- <sup>9</sup>School of Dentistry, Shenzhen University Medical School; Shenzhen, 518037, China.
- <sup>10</sup>Jiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical
   College, Nanchang University; Nanchang, 330008, China.
- <sup>11</sup>Clinical Research Design Division, Clinical Research Center, Sun Yat-sen Memorial
   Hospital, Sun Yat-sen University; Guangzhou, 510120, China.
- <sup>12</sup>Lecturer, Department of Gastroenterological Surgery, Faculty of Medicine, Fukuoka
   University; Fukuoka, 814-0180, Japan.
- <sup>13</sup>Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing
   University; Chongqing, 400038, China.
- <sup>14</sup>Cancer Institute, Xuzhou Medical University; Xuzhou, 221004, China.
- <sup>15</sup>Department of Surgery, Massachusetts General Hospital, Harvard Medical School; Boston,
   02115, USA.
- <sup>16</sup>Faculty of Life and Health Sciences, Shenzhen University of Advanced Technology;
   Shenzhen, 518107, China.
- <sup>17</sup>Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced
   Technology, Chinese Academy of Sciences; Shenzhen, 518055, China.

43	<sup>18</sup> GMU-GIBH Joint School of Life Sciences, The Fifth Affiliated Hospital of Guangzhou
44	Medical University, Guangzhou Medical University; Guangzhou, 510005, China.
45	
46	
47	* Corresponding author. Email:
48	XWANG30@mgh.harvard.edu (X.W.); fang.xu@siat.ac.cn (F.X.);
49	fan_xiaoying@gzlab.ac.cn (X.F.); fansong2@mail.sysu.edu.cn (S.F.).
50	<sup>#</sup> These authors contributed equally to this work.
51	<sup>†</sup> Deceased 10 January 2023.
52	

53

Abstract: Recent advancements in cancer immunotherapy have improved patient 54 outcomes, yet responses to immunotherapy remain moderate. We conducted a Phase II 55 clinical trial (NCT04718415) involving 51 cancer patients undergoing neoadjuvant 56 chemoimmunotherapy and applied single-cell RNA and T/BCR sequencing on tumor and 57 blood samples to elucidate the immune cell perturbations. Our findings associate poor 58 response with reduced levels of CCR7<sup>+</sup>CD4 Naïve T cells and CD27<sup>+</sup> Memory B cells, as 59 well as higher expression of immunosenescence-related genes in T and B cell subsets. Using 60 naturally aged and  $Ercc1^{+/-}$  transgenic aging mouse models, we found that senolytics 61 enhance the therapeutic efficacy of immunotherapy in multiple solid tumors by mitigating 62 tumor immunosenescence. Notably, we launched a Phase II clinical trial, COIS-01 63 (NCT05724329), which pioneers the combination of senolytics with anti-PD-1 therapy. The 64

clinical results demonstrate that this therapeutic strategy is associated with a favorable safety profile and therapeutic efficacy, significantly mitigating adverse effects and alleviating immunosenescence. These findings underscore the pivotal role of immunosenescence characteristics in influencing the effectiveness of immunotherapy and suggest a promising therapeutic efficacy along with a beneficial safety assessment for the combination of senolytics with anti-PD-1 therapy.

71 Main Text:

Despite recent advancements in blocking the PD-1/PD-L1 pathway, which have 72 revolutionized the treatment of solid tumors, only a small fraction of patients benefits from 73 immunotherapy, with fewer than 20% showing sustained responses  $^{1-3}$ . A major challenge in 74 current immunotherapy and neoadjuvant strategies is our limited understanding of the highly 75 dynamic and heterogeneous tumor immune microenvironment (TIME), which impacts treatment 76 responses <sup>4-6</sup>. The concept of cancer immunoediting emphasizes the immune system's dual role 77 in inhibiting tumor growth and shaping tumor immunogenicity. This process is described in three 78 stages: elimination, equilibrium, and escape. During the elimination phase, the host's innate and 79 adaptive immune systems recognize and respond to tumor-specific antigens <sup>7,8</sup>. T cells are the 80 81 primary players in tumor immunity. Although tumor-reactive T cells are present in TIME, the phenotypic heterogeneity of T cells across different tumors and their divergent differentiation 82 fates remain significant. Exhaustion still poses a major limitation to their anti-tumor potential 83 9,10 84

Immunosenescence, a well-established phenomenon occurring with age, results in the immune system losing its ability to effectively respond to pathogens and cancer cells <sup>11–15</sup>. Recent studies have uncovered the complex role of immunosenescence in tumors, with factors

88	such as cAMP, glucose competition, and oncogenic stress in the TIME inducing senescence in T
89	cells, macrophages, natural killer (NK) cells, and dendritic cells, thereby impairing their immune
90	cytotoxic function against tumors <sup>16</sup> . However, it remains unclear whether individual differences
91	in immunosenescence affect the efficacy of immunotherapy in cancer patients.
92	Previous studies have shown that blocking DNA damage signals can inhibit the senescence of
93	tumor-infiltrating T cells, thereby enhancing the efficacy of immune checkpoint inhibitors (ICIs)
94	against tumors <sup>17</sup> . Recent research also indicate that chronic inflammation caused by an aging

immune system can promote cancer development, regardless of the age of the cancerous or
surrounding tissues <sup>18</sup>. Therefore, we believe that the senescence status of immune cell
subpopulations, which play a crucial role in tumor immunity, may be critical for treatment
outcomes. We hypothesize that senolytics can be combined with ICIs to enhance their efficacy in
treating solid tumors.

In this study, we first explored the variability in patient responses to neoadjuvant 100 101 immunotherapy, starting with a Phase II clinical trial in head and neck squamous cell carcinoma (HNSCC, NCT04718415). Further analysis of single-cell RNA sequencing (scRNA-Seq) data 102 from these patients allowed us to identify key immune cell subpopulations that influence 103 immune responses and to reveal the negative impact of immunosenescence on immunotherapy 104 efficacy. Additionally, animal study data highlighted the potential benefits of combining 105 senolytics with ICIs for treating solid tumors, including HNSCC, bladder cancer, and breast 106 cancer. We then initiated a pioneering Phase II clinical trial (COIS-01, NCT05724329) to 107 evaluate the efficacy and safety of combining anti-aging drugs with ICIs in HNSCC patients. 108 109 Our results indicate that the neoadjuvant combination of senolytics and ICIs significantly reduces toxic side effects compared to neoadjuvant chemotherapy. Furthermore, patients receiving the 110 combination therapy exhibited a higher proportion of CCR7<sup>+</sup> naïve T cells within their tumors, 111

suggesting a mitigation of immunosenescence and an enhancement of the adaptive immuneresponse.

# Phase II trial evaluating neoadjuvant chemotherapy combined with immunotherapy for oral cavity and oropharyngeal squamous cell carcinoma (OOC-001)

We enrolled 51 patients with stage II-IVA HNSCC for neoadjuvant chemoimmunotherapy 116 117 (OOC-001, NCT04718415). One patient was excluded from the evaluation due to refusing to continue the treatment (Extended Data Fig. 1a). All patients underwent a minimum of two cycles 118 of neoadjuvant treatment, with 24 (47.1%) receiving 2 cycles, 23 (45.1%) receiving 3 cycles, and 119 4 (7.8%) receiving 4 cycles of neoadjuvant treatment (Supplementary Tables 1-4). Among the 48 120 evaluable patients, 23 patients achieved pathological complete response (pCR, 47.9%), 8 patients 121 122 achieved major pathological response (MPR, 16.7%), 10 patients showed partial pathological response (pPR, 20.8%), and 7 patients displayed pathological no response (pNR, 14.6%) (Fig. 1a, 123 Extended Data Fig. 1b). The comparison of radiologic and pathologic response indicators 124 125 suggested that certain patients were pathologically assessed as pCR while radiologically assessed as PR (Partial response)/SD (Stable disease), highlighting significant inconsistency between 126 pathological and radiological assessments (Fig. 1b). Compared to the baseline, 72.7% of primary 127 tumors exhibited shrinkage, while only 46.7% of patients showed regression in lymph nodes, 128 possibly indicating that primary tumors in HNSCC are more sensitive to neoadjuvant therapy 129 (Fig. 1c and Extended Data Fig. 1c-e). Regarding treatment cycles, pathological assessment 130 suggested that the efficacy of the 2-cycle treatment might be less than that of 3 or 4 cycles 131 (Extended Data Fig. 1f). 48 patients (94%) experienced at least one treatment-related adverse 132 133 effect (TRAE). Grade 3-4 TRAEs were observed in 26 patients (51%), and the most common TRAEs were alopecia (75%), asthenia or fatigue (53%), and nausea (49%) (Supplementary Table 134

135 2).

The 24-month overall survival (OS) for the cohort was 93.9% (Extended Data Fig. 1g, h). Our findings show that combining sintilimab with carboplatin and nab-paclitaxel resulted in manageable side effects and achieved a high overall response rate (64.6%, MPR and pCR). Considering the trade-off between anti-tumor effectiveness and adverse effects, we observed that a 3-cycle treatment regimen offered superior benefits for patients with HNSCC.

141

### Immune landscape of HNSCC patients with neoadjuvant chemoimmunotherapy

ScRNA-Seq and scT/BCR-Seq was performed in seven treatment-naïve tumor samples and nine blood samples (including pre-and post-treatment) (Fig. 1d, Supplementary Table 3). Following quality filtering, we obtained scRNA-Seq profiles as well as TCR and BCR clonotypes from 143,056 cells, encompassing T cells, NK cells, B cells, myeloid cells, fibroblasts, endothelium, and tumor cells (Supplementary Figure 1a-f). A total of 27 cell clusters with distinct molecular features were observed by re-clustering each major immune cell type (Fig. 1e).

We analyzed the abundance of various immune subtypes and compared their proportions 149 150 across the tumor, pre-treatment blood (P0) and post-treatment blood (P1) of MPR and noMPR patients. The proportion of CD4<sup>+</sup> T cells showed the largest elevation among all immune cell 151 types when comparing P1 to P0 (Supplementary Figure 1g, h). While compared to noMPR 152 153 patients, MPR patients' tumors exhibited higher proportions of CCR7<sup>+</sup>CD4 Naïve T cells, CXCL13<sup>+</sup>CD4 T cells, GZMK<sup>+</sup>CD8 Tem cells, and CD27<sup>+</sup> Memory B cells. Conversely, the 154 proportions of FOXP3<sup>+</sup>CD4 Treg cells and IGF1<sup>+</sup> macrophages (IGF1<sup>+</sup> M $\phi$ ) were lower (Fig. 1f 155 and Supplementary Figure 2, 3a-f). The upregulated genes in noMPR patients of the main T/B 156 cell subtypes were involved in aging-related pathways, indicating these pathways may contribute 157 158 to variations in the treatment response status of HNSCC patients. (Supplementary Figure 3g,

159 Supplementary Table 5). Using T/BCR diversity as markers of antigenic immune responses to neoadjuvant therapy, we investigated TCR and BCR clonality in MPR and noMPR groups 160 through three different methods (Chao1, Shannon Index, and Richness). The results showed that 161 MPR patients exhibited higher TCR and BCR clonal diversity in CCR7<sup>+</sup>CD4 Naïve T cells, 162 CXCL13<sup>+</sup>CD4 T cells, GZMK<sup>+</sup>CD8 Tem cells, and CD27<sup>+</sup> Memory B cells (Fig. 1g and 163 Supplementary Figure 3h). Additionally, dominant clones present in the tumor and blood before 164 treatment persisted as the dominant clones after treatment in MPR patients (Extended Data Fig. 165 2a-c). Further analysis of TCR/BCR clonotypes from P0, P1, and tumors revealed no significant 166 167 differences in TCR/BCR clonotypes in blood before and after treatment, nor between MPR and noMPR patients. Interestingly, MPR patients exhibited a greater number of unique TCR/BCR 168 clonotypes within tumors, suggesting a richer TCR/BCR clonal diversity (Extended Data Fig. 2d, 169 170 e).

Immunosenescence refers to the decline in the immune system's ability to effectively 171 respond to pathogens and cancer cells<sup>11</sup>. Recent studies have found that characteristics of 172 immunosenescence include an imbalance in the proportion of naïve and memory T cells, a 173 decrease in the number of TCR clones, and elevated levels of  $p16^{INK4a}$  (also known as *CDKN2A*) 174 and  $p21^{CIP1}$  (CDKN1A) expression <sup>19,20</sup>. We then examined the expressions of the senescent 175 markers, P16 and P21, by immunostaining in tumor tissues from two clinical trials conducted at 176 our center (OOC-001 and REDUCTION-I, NCT05582265). The results revealed that the tumor 177 microenvironment of noMPR patients exhibited higher levels of senescent features (Fig. 1h and 178 Extended Data Fig. 2f). In summary, our data suggests that non-responsive patients to 179 neoadjuvant treatment demonstrate dysregulation in immune cell proportions and an increase in 180 senescent characteristics. 181

# T cell and B cell subtypes exhibiting senescent features influence the response to immunotherapy

Recent studies have shown that in late life, the aging individual's adaptive immune system 184 exhibits dysfunction and increased autoimmunity, with T and B cell aging being a primary 185 manifestation of immunosenescence<sup>21,22</sup>. However, there is no gold standard marker for defining 186 the senescence of T and B cells  $^{23}$ . To figure out this assumption, we first created an 187 immunosenescence-associated gene set (IAGs) consists of 154 genes based on extensive scRNA-188 Seq datasets differentiating immune cells from young and elderly individuals (Extended Data Fig. 189 3a, Supplementary Table 6). The IAGs were significantly enriched in the immune cells of elderly 190 individuals in three independent scRNA-Seq datasets (GSE157007<sup>24</sup>, GSE141595<sup>25</sup> and 191 PRJCA002856) (Fig. 2a and Extended Data Fig. 3b-d), indicating they could reflect human 192 immunosenescence characteristics. Additionally, evaluating IAGs in scRNA-Seq datasets for 193 HNSCC and triple-negative breast cancer (TNBC)<sup>26</sup> immunotherapies also revealed lower 194 senescent scores in MPR patients compared to noMPR patients (Extended Data Fig. 3e). 195 Subsequently, we used IAGs to score T cells and their subtypes, which revealed lower 196 immunosenescence features in MPR patients with HNSCC (Fig. 2b and Extended Data Fig. 4a). 197 Furthermore, we also identified senescent genes associated with T cells from the IAGs, which 198 showed higher expression levels in multiple T cell subgroups of noMPR patients, with GO 199 analysis revealed enrichment in pathways related to S100 protein binding (Fig. 2c and Extended 200 Data Fig. 4b, c). Similar results were obtained from the TNBC dataset (Extended Data Fig. 4d-h). 201 Relative to noMPR patients, MPR patients exhibited lower  $V\alpha/\beta$  gene usage frequencies in 202

CCR7<sup>+</sup>CD4 T cells and FOXP3<sup>+</sup>CD4 Treg cells in both tumors and blood, consistent with previous findings (Extended Data Fig. 5a). Pseudotime analysis of immune cells revealed that  $CD4^+$  T cell subsets in peripheral blood exhibit an early differentiation phenotype, while their

tumor counterparts show a more differentiated phenotype. Notably, MPR patients demonstrated
 differentiation towards CCR7<sup>+</sup>CD4 Naïve T cells and CXCL13<sup>+</sup>CD4 Th cells, maintaining T cell
 vitality and the potential to differentiate into various functional subtypes. In contrast, CD4<sup>+</sup> T
 cells in non-MPR patients tended to differentiate towards FOXP3<sup>+</sup>CD4 Tregs, leading to
 immunosenescence-related characteristics (Extended Data Fig. 5b-d).

Numerous T cells demonstrate shared clonotypes between tumors and blood. These clonal T 211 cells in tumor showed elevated IAGs scores than those in blood, suggesting a higher level of 212 senescent characteristics for the tumor-infiltrating T cells (Fig. 2d, e). Analysis of paired TCR 213 data revealed a notable reduction of both unique and total clonotypes particularly in the 214 CCR7<sup>+</sup>CD4 Naïve T cells in noMPR patients compared with MPR patients (Fig. 2f). 215 Immunosenescence features are notably pronounced in B cells of noMPR patients, particularly in 216 CD27<sup>+</sup> Memory B cells (Extended Data Fig. 6a-e). Pairwise analysis of T and B cell receptors 217 and ligands revealed strong interactions between FOXP3<sup>+</sup>CD4 Treg cells and CXCL13<sup>+</sup>CD4 T 218 helper cells with B cells (Extended Data Fig. 6f). This indicates that in MPR patients, the 219 reduced number of FOXP3<sup>+</sup>CD4 Tregs and increased number of CXCL13<sup>+</sup>CD4 T helpers may 220 exert their effects through interactions with B cells. 221

Through immunofluorescence staining, we confirmed that  $CD4^+$  T cells and  $CD27^+$ 222 memory B cells expressing the senescent marker S100A11 were more abundant in noMPR 223 patients, while no difference was observed in the number of S100A11<sup>+</sup>CD8 T cells between 224 noMPR and MPR patients, suggesting senescent status of CD4 T cells critically modulate 225 patients' response to neoadjuvant therapy (Fig. 2g and Extended Data Fig. 6g). Analysis of 226 227 HNSCC Patients' data from the TCGA database found that patients with high expression of IAGs such as S100A11, AREG, CALD1, CDKN1A, and CASP4 together with low CD4 Naïve T cell or 228 memory B cell abundance had significantly worse prognosis than those with low expression of 229

senescent genes and high proportions of CD4 Naïve T cells or memory B cells (Fig. 2h and
Supplementary Figure 4). T cells predict responses to immunotherapy more effectively in
HNSCC patients, while in TNBC patients, B cells are more predictive (Fig. 2i). These analyses
suggest that the IAGs we constructed were effective in distinguishing the immune cells of
noMPR and MPR patients, and that lower expression levels of IAGs in CCR7<sup>+</sup>CD4 Naïve T and

235 CD27<sup>+</sup> Memory B cells are associated with a positive treatment response.

236

### IGF1<sup>+</sup> M $\phi$ induce senescent characteristics in T cells

Innate immune cells play an important role in early tumor cell recognition and subsequent 237 initiation of inflammation and antitumor responses. To investigate whether non-lymphocyte 238 immune cells are involved in the immunosenescence phenotype observed in our study subjects, 239 we analyzed the gene expression features of myeloid cells.  $IGF1^+$  M $\phi$  exhibited the highest 240 differentiation score among all myeloid cell types according to pseudotime analysis (Extended 241 Data Fig. 7a). The precursor cells of IGF1<sup>+</sup> Mo in the blood are IL1B-CD14 cells, which showed 242 significant changes in the MPR group before and after treatment. Interestingly, the proportion of 243  $IGF1^+ M\phi$  within tumors and IL1B-CD14 cells in blood were significantly higher in noMPR 244 patients (Fig. 2j and Extended Data Fig. 7b-d). Additionally, IGF1<sup>+</sup> Mo negatively correlated 245 with CCR7+CD4 Naïve T cells and CD27+ Memory B cells in tumors (Fig. 2k). We also 246 examined the composition proportions of myeloid cell subtypes in TNBC patients and found that 247 PR patients had a higher proportion of IGF1<sup>+</sup> M $\phi$  compared to SD patients, consistent with our 248 HNSCC results (Extended Data Fig. 7e, f). By scoring the expression of six major senescence-249 associated secretory phenotype (SASP) factors in HNSCC and TNBC, we found that IL1B-250 CD14 monocytes and IGF1<sup>+</sup> M $\phi$  expressed higher levels of SASP factors compared to other 251 myeloid cell subtypes (Extended Data Fig. 7g, h). Interaction analysis further revealed that 252  $IGF1^+$  M $\phi$  had a strong potential for interaction with T cells (Supplementary Figure 5a-c). 253

254 Enrichment analysis of pathways related to IGF1<sup>+</sup> Mo and IL1B-CD14 cells revealed involvement in senescent and inflammatory pathways, including ERK, MAPK and IL-1 255 pathways. Consequently,  $IGF1^+$  M $\phi$  in the TIME may induce immunosenescence in T cells. 256 Analysis of TCGA data for HNSCC patients demonstrated that those with high IGF1 signature 257 had relatively poor OS and progression-free survival (PFS) (Extended Data Fig. 7i and 258 Supplementary Figure 5d, e). In conclusion, our analysis of myeloid cell subtypes suggests that 259  $IGF1^+$  M $\phi$  could be a crucial factor contributing to the limited response of tumor patients to 260 immunotherapy. These cells may trigger an immunosenescent status in the TIME through their 261 interactions with T cells. 262

#### 263

### Senolytics combined aPD-1 alleviate TIME senescent burden in HNSCC

Currently, the role of the senescent phenotype in HNSCC and its interaction with tumor 264 cells, immune cells, or other cell types remains poorly understood. The impact of senolytics 265 treatments or their combination with other therapies in HNSCC is yet to be determined. 266 Histochemical staining with  $\beta$ -galactosidase revealed a significantly more pronounced senescent 267 phenotype in HNSCC tissue compared to the adjacent normal tissue (Fig. 3a). Then, we 268 established a 4-NQO-induced (4-Nitroquinoline-N-oxide) HNSCC mouse model using 12-269 month-old C57BL/6 (C57) mice (Fig. 3b). The mice underwent the typical progression of normal 270 epithelium-epithelial dysplasia-invasive cancer, with an average age of tumor occurrence around 271 20 months, reflecting the real progression of HNSCC in elderly patients more accurately 272 (Extended Data Fig. 8a). Immunofluorescence staining on tumor sections confirmed significantly 273 higher expression of the key senescent marker P16 in the tumor region compared to surrounding 274 275 normal tissue (Fig. 3c).

276	To further investigate the effect of senolytics on HNSCC, we randomly divided the 4-NQO-
277	induced tumor mice into four groups, administering Isotype, αPD-1 (anti PD-1), αPD-1+CP (anti
278	PD-1+Cisplatin), or aPD-1+DQ (anti PD-1+Dasatinib+Quercetin) treatments (Fig. 3b). The
279	$\alpha$ PD-1+DQ group exhibited fewer lesions compared to other groups. Interestingly, there was no
280	significant difference between the $\alpha$ PD-1 group and the $\alpha$ PD-1+CP group (Fig. 3d and Extended
281	Data Fig. 8b) while aPD-1+DQ group had a longer lifespan compared to other groups (Fig. 3e
282	and Extended Data Fig. 8c). Moreover, flow cytometry revealed that $\alpha$ PD-1+DQ treatment
283	effectively decreased $\beta$ -galactosidase expression in CD45 <sup>+</sup> immune cells within tumors (Fig. 3f).
284	Correlation analysis further demonstrated a negative relationship between mice survival time and
285	$\beta$ -galactosidase expression in immune cells, confirming the anti-tumor effect of $\alpha$ PD-1+DQ by
286	reversing immunosenescence in HNSCC mice (Fig. 3g).

Subsequently, we evaluated changes in CD4<sup>+</sup>, CD8<sup>+</sup>, and B220<sup>+</sup> cells in the spleen, blood, 287 bone marrow, and tumors across different treatment groups using flow cytometry. The aPD-288 1+DO group showed an increased proportion of CD4<sup>+</sup> cells within tumors, while CD8<sup>+</sup> and 289 B220<sup>+</sup> cell levels exhibited no significant differences compared to other groups (Fig. 3h). Similar 290 results were observed in the spleen (Extended Data Fig. 8d, e). However, B220<sup>+</sup> cell counts were 291 relatively elevated in peripheral blood samples from the αPD-1+DQ group (Extended Data Fig. 292 8f-g). Additionally, the expression levels of p16 and p21 were significantly reduced in tumor-293 infiltrating CD4<sup>+</sup> cells from the  $\alpha$ PD-1+DQ group (Fig. 3i), whereas no significant differences 294 were noted in CD8<sup>+</sup> cells (Extended Data Fig. 8h). Furthermore, an increased proportion of 295  $CD62L^+CD44^-$  naïve  $CD4^+$  cells was observed in the  $\alpha PD-1+DQ$  group (Fig. 3j). 296 Immunofluorescence staining consistently confirmed a significant increase in CD4<sup>+</sup>CD62L<sup>+</sup> cells 297 in the  $\alpha$ PD-1+DQ group relative to the other groups (Fig. 3k and Supplementary Figure 6). 298 Together, these findings suggest that immunosenescence in HNSCC surpasses that in 299

surrounding normal tissue, and the combination of  $\alpha$ PD-1+DQ may enhance the therapeutic efficacy of  $\alpha$ PD-1 by mitigating the senescent phenotype of tumor immune cells, particularly in CD4<sup>+</sup> cells.

# 303 Synergistic reduction of SASP and increase in CD4<sup>+</sup> Naïve T cells by senolytics and αPD-1 304 in solid tumors

To determine the effectiveness of  $\alpha$ PD-1+DO in various transplant tumor models, including 305 HNSCC, we established two mouse oral squamous cell carcinoma cell lines, 4N-MS1 and 4N-306 MS2, from the 4-NOO model (Fig. 4a, Extended Data Fig. 9a, b). To simulate the systemic 307 senescence in normal elderly mice, we used  $Ercc1^{+/-}$  mice, which exhibit rapid senescent 308 characteristics such as hair loss and graving like 20-month-old wild-type mice by the age of 10 309 months (Fig. 4b). Further measurements of spleen weight and 8-hydroxy-2-deoxyguanosine (8-310 OHdG) content in the spleen showed that  $Ercc1^{+/-}$  10m mice had similar 8-OHdG levels and 311 spleen weight as WT 20m mice. Immunofluorescence staining revealed that 10-month-old 312  $Ercc1^{+/-}$  mice expressed more  $\gamma$ H2AX in the spleen, heart, liver, and lungs compared to wild-313 type mice (Fig. 4c-e). In summary, Ercc1<sup>+/-</sup> 10m mice exhibited senescent characteristics like 314 naturally aging wild-type mice. 315

We implanted 4N-MS1cells into the tongues of 10-month-old *Ercc1*<sup>+/-</sup> mice and, on the 5th day, treated the mice with Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP, or  $\alpha$ PD-1+DQ (Fig. 4f). Tumor growth curves showed that mice in the  $\alpha$ PD-1+DQ group had better treatment outcomes than other groups (Fig. 4g). Additionally, we employed the Multiplex bead-based protein analysis method to measure the expression of various SASP factors in tumor tissue lysates. The results revealed that  $\alpha$ PD-1+DQ treatment significantly reduced the expression of various SASP factors within the tumor, including IL-2, TNF- $\alpha$ , IFN- $\gamma$ , IL-10, CCL20, MCP-3, and others (Fig. 4h and

323 Supplementary Table 7). Furthermore, flow cytometric analysis showed an increase in  $CD62L^{+}CD44^{-}CD4^{+}$  Naïve cells in the  $\alpha$ PD-1+DQ group compared to the Isotype group (Fig. 4i). 324 Consistently, immunofluorescence staining confirmed a significant decrease of P21<sup>+</sup> cells in the 325  $\alpha$ PD-1+DO group compared to the other three groups (Fig. 4j). Moreover, we implanted MB49 326 (bladder cancer) and E0771 (breast cancer) tumors subcutaneously in 10-month-old Ercc1<sup>+/-</sup> 327 mice and observed therapeutic outcomes like those seen with the 4N-MS1 transplant model. (Fig. 328 4k and Extended Data Fig. 9c-f). In summary, these data suggest that  $\alpha$ PD-1+DO treatment can 329 suppress tumor growth in multiple solid tumors while enhancing immune microenvironment 330 vitality through reduced SASP and increased CD4<sup>+</sup> Naïve cells. 331

# 332 Senolytics reduce senescent characteristics and enhance activation of tumor-infiltrating 333 CD4<sup>+</sup> Naïve T cells

To investigate the unique functionality of significantly increased CD4<sup>+</sup>CD62L<sup>+</sup> Naïve T 334 cells in tumors after combined aPD-1+DQ therapy in anti-tumor immunity, we isolated 335 336  $CD62L^+CD44^-CD4^+$  cells from tumors of mice treated with Isotype,  $\alpha PD-1$ , or  $\alpha PD-1+DQ$ , and performed RNA-Seq and ATAC-Seq (Fig. 5a). The results of RNA-Seq showed that, compared 337 to Isotype or  $\alpha$ PD-1 treatment, the  $\alpha$ PD-1+DQ group exhibited significantly higher expression of 338 genes related to T-cell migration (*Ccr7*) or antigen response (*Lck*, *Cfd*) in Naïve T cells (Fig. 5b, 339 Extended Data Fig. 10a and Supplementary Table 8). GO analysis revealed enrichment in 340 pathways related to T-cell maintenance, differentiation, and antigen presentation for both  $\alpha$ PD-341 1+DQ and Isotype groups, indicating that the combination of senolytics with  $\alpha$ PD-1 may 342 enhance immune response levels by promoting proliferation and differentiation of Naïve T cells 343 (Fig. 5c and Extended Data Fig. 10b). Additionally, ATAC-Seq analysis demonstrated that, 344 relative to Isotype or aPD-1 treatment, the aPD-1+DQ group exhibited significantly higher 345 chromatin accessibility of the Ccr7 gene, crucial for adaptive immune responses. Conversely, 346

347	genes associated with immunosenescence and chronic inflammation, such as S100a11, showed
348	lower chromatin accessibility (Fig. 5d, Extended Data Fig. 10c-g and Supplementary Table 9).
349	Furthermore, joint GO analysis of RNA-Seq and ATAC-Seq results from the $\alpha$ PD-1+DQ and
350	Isotype groups yielded similar findings (Fig. 5e). qPCR measurements confirmed that $\alpha$ PD-
351	1+DQ treatment upregulated genes associated with T cell activation, such as Ccr7, Lck, and Cfd,
352	and downregulated genes linked to immunosenescence, including p16, p21, and S100a11, in
353	tumor-infiltrating CD4 <sup>+</sup> Naïve T cells. (Fig. 5f). Additionally, flow cytometry and
354	immunofluorescence staining also demonstrated a significant increase in CCR7 and LCK-
355	positive CD4 <sup>+</sup> Naïve T cells following aPD-1+DQ treatment (Fig. 5g, h). In conclusion, our
356	results indicate that $\alpha$ PD-1+DQ treatment effectively reduces the senescent phenotype while
357	markedly enhancing the quantity and differentiation potential of tumor-infiltrating CD4 <sup>+</sup> Naïve T
358	cells.

# 359 Combination of anti-PD-1 with Dasatinib and Quercetin Demonstrates Safety and Efficacy 360 in Patients with HNSCC.

Previous studies have indicated that neoadjuvant chemotherapy reduces recurrence in 361 patients with locally advanced oral cancer but does not improve survival rates <sup>27,28</sup>. Recent 362 research indicates that chemotherapy can exacerbate the adverse effects associated with 363 immunotherapy. The most prevalent adverse effects of neoadjuvant immunochemotherapy 364 include alopecia (100.0%), nausea/vomiting (60.4%), and fatigue (50.0%)<sup>29</sup>. Therefore, it is 365 essential to investigate novel therapeutic agents that can enhance the efficacy of immunotherapy 366 while minimizing systemic side effects, preserving the function of vital organs, and ultimately 367 improving the quality of life for patients. 368

Based on our findings from single-cell multi-omics analysis and animal models, we 369 hypothesized that combining ICIs with dasatinib and quercetin would be both effective and safe 370 for patients with HNSCC, significantly reducing TRAEs compared to standard neoadjuvant 371 chemotherapy. To evaluate this hypothesis, we conducted a prospective, open-label, single-372 center, Phase II clinical trial (COIS-01), assessing the neoadjuvant efficacy of tislelizumab 373 combined with dasatinib and quercetin in resectable HNSCC patients. The primary endpoint of 374 the study was the MPR rate (Fig. 6a). Between February 5, 2023, and April 5, 2024, a total of 24 375 patients were enrolled according to the study protocol. Efficacy evaluations revealed that 4 376 377 patients (16.7%) achieved a pCR, while another 4 (16.7%) achieved a MPR, resulting in an overall treatment response rate of 33.3% (pCR + MPR) (Fig. 6b and Supplementary Table 10). 378 Representative imaging, pathological assessments, and clinical photographs of patients achieving 379 380 pCR are provided (Fig. 6c).

Safety analyses of the 24 patients demonstrated that only 1 patient experienced grade 3-4 381 TRAEs (Fig. 6d). In contrast, the OOC-001 trial, which evaluated neoadjuvant chemotherapy, 382 showed the most common TRAEs were alopecia (75%), asthenia or fatigue (53%), and nausea 383 (49%) (Fig. 6e, Supplementary Table 2). In the COIS-01 trial, the corresponding incidences were 384 notably lower, with 0% for alopecia, 25% for asthenia or fatigue, and 16.7% for nausea 385 (Supplementary Table 11). Although the survival period in COIS-01 has not yet allowed for 386 statistical analysis of overall survival, no recurrences or deaths have been observed to date. 387 Furthermore, immunohistochemical analysis of patient paraffin sections before and after  $\alpha$ PD-1 388 + DQ treatment revealed an upregulation of CCR7 expression in naïve T cells post-treatment 389 (Fig. 6f). These early findings from the COIS-01 trial suggest that the combination of 390 tislelizumab with dasatinib and quercetin demonstrates promising antitumor efficacy, favorable 391 392 tolerability, and a potential to mitigate immunosenescence-related features.

393

#### 394 Discussion

The central conclusion of this study is that the senescence of TIME is a critical factor 395 affecting the efficacy of tumor immunotherapy. The first evidence supporting this conclusion 396 comes from the multidimensional single-cell data analysis of immune cells from both blood and 397 tumors of patients in clinical trials. We observed that noMPR patients exhibited more 398 pronounced immunosenescence features, including a decreased proportion of naïve T cells and 399 memory B cells, an increased proportion of immunosuppressive cell subtypes, and a reduction in 400 the TCR/BCR repertoire. Additionally, we identified IAGs in immune cells from noMPR 401 patients, which showed higher expression levels across various T and B cell subsets. When 402 tumor-bearing mice received a combination of ICI and senolytics, we observed an increase in 403 CD4<sup>+</sup> naïve T cells and a reduction in senescence markers in immune cells within the tumors. 404 This led to reduced tumor burden and extended survival in the mice. A clinical trial based on our 405 findings further confirmed the potential advantage of combining ICI with senolytics for treating 406 solid tumors. 407

Immune cells are the cornerstone of tumor immunotherapy <sup>30,31</sup>. T cell-centered therapies 408 have become powerful tools against cancer. ICI is the most widely used immunotherapy method 409 for solid malignancies, with an increasing number of monoclonal antibodies targeting different 410 inhibitory receptors entering clinical practice <sup>32</sup>. Antibodies against PD-1, CTLA-4, and LAG-3 411 have been FDA-approved for several types of solid tumors. Although ICI can induce objective 412 responses even in the challenging context of metastatic disease, only a minority of patients 413 (estimated at <30%) achieve sustained and/or complete clinical responses <sup>33–35</sup>. The TIME is rich 414 in tumor-reactive T cells, but exhaustion remains a major factor limiting their antitumor 415

capabilities. Studies on chronic antigen stimulation models in mice <sup>36–38</sup> and the characteristics of
tumor-infiltrating lymphocytes (TILs) in human "hot" tumors <sup>39–41</sup> emphasize that antitumor T
cells can progressively acquire a dysfunctional state, allowing tumor immune evasion <sup>42,43</sup>. These
findings suggest that the TIME is not isolated but interconnected with the systemic immune
system. The dynamic processes of TILs dysfunction and continuous recruitment of immune cells
to the tumor provide a new perspective for exploring ways to improve the TIME during tumor
progression.

Notably, our study shows no significant differences in the proportions of most immune cell 423 types in the peripheral blood of responsive and non-responsive patients before and after 424 treatment. This indicates that predicting immunotherapy responses based on peripheral blood 425 tests may be challenging. Although cellular senescence drives various age-related complications 426 through SASP, identifying senescent immune cells in vivo remains difficult <sup>44–46</sup>. Recent studies 427 have identified a set of genes (SenMayo) enriched in bone biopsies from elderly individuals, 428 capable of identifying senescent hematopoietic or stromal cells at the single-cell level in human 429 and mouse bone marrow/bone scRNA-Seq data <sup>46</sup>. Researchers also established AgeAnno, a 430 human aging single-cell annotation knowledge base, offering dynamic functional annotations of 431 1,678,610 cells from 28 healthy tissue samples <sup>47</sup>. Currently, there are no specific markers or 432 gene sets dedicated to reflecting the degree of immunosenescence. We have constructed an 433 immunosenescence-related gene set comprising 154 genes (IAGs), which has effectively 434 distinguished between young and elderly individuals in external datasets. This provides a 435 powerful tool for future research on the senescent status of the immune system. It is important to 436 note that the immune system consists of diverse cell types, each with distinct functions. For 437 example, the gene expression profiles of senescent states in T cells, dendritic cells, and 438

macrophages may differ significantly. Understanding these differences is crucial for developing
 targeted therapies for senescent phenotypes.

Senolytics therapies for various cancers are currently under investigation. Studies have 441 shown that senolytics ABT-263 can exert antitumor effects by selectively clearing senescent 442 cells in obese patients' tumor tissues <sup>48</sup>. Additionally, the plant compound Rutin, when combined 443 with chemotherapy, can intervene in tumor development <sup>49</sup>. These studies suggest that senolytics 444 may offer unique advantages in cancer treatment, with fewer side effects and promoting overall 445 systemic health. However, the combination of senolytics and ICI has not been explored in TIME. 446 Previous research discussed the potential benefits of DQ therapy, a novel senolytics regimen that 447 disrupts survival pathways of senescent cells and selectively targets them 50-52. Recent research 448 on systemic administration of DO for treating intervertebral disc degeneration has provided new 449 insights, highlighting the tissue-specific effects of DO and the importance of treatment timing  $5^3$ . 450 Additionally, a clinical trial on DO treatment for idiopathic pulmonary fibrosis (IPF) 451 demonstrated significant improvements in patients' physical function <sup>54,55</sup>. Our COIS-01 trial has 452 demonstrated the efficacy and safety of combining senolytics with ICIs in HNSCC patients. 453 Previous studies have shown that ICIs monotherapy in HNSCC has limited effectiveness, with 454 reported MPR rates of 7-13.9% 56-58. In contrast, the COIS-01 trial achieved an MPR rate of 455 33.3%. While immunochemotherapy can achieve higher MPR rates, it is associated with 456 significant toxicity, with grade  $\geq 3$  adverse events occurring in up to 35% of patients <sup>59</sup>. 457 substantially higher than in the COIS-01 trial, where the incidence of such events was 458 considerably lower (4.2%). Grade  $\geq$ 3 toxicities can severely impact patient quality of life and 459 pose challenges for subsequent adjuvant immunotherapy. Discontinuation of adjuvant 460

461 immunotherapy due to toxicity may compromise the overall therapeutic efficacy, potentially 462 affecting survival outcomes  $^{60}$ .

Given this balance between efficacy and risk, the COIS-01 trial offers a novel therapeutic 463 strategy that maximizes the antitumor efficacy of ICIs while minimizing adverse events. 464 Preclinical studies in multiple mouse models have demonstrated the superior potential for long-465 term survival with the combination of  $\alpha$ PD-1 and senolytics (dasatinib and guercetin) compared 466 to monoimmunotherapy or immunochemotherapy. Consistently, the combination of senolytics 467 and anti-PD-1 therapy has been shown to dramatically upregulate CCR7<sup>+</sup> naïve T cells in COIS-468 01 patients, a critical feature in the modulation of immunosenescence <sup>61</sup>. This upregulation 469 enhances the homing <sup>62</sup>, immune surveillance <sup>63</sup>, and circulating maintenance <sup>64</sup> of these specific 470 T cells, potentially predicting improved survival outcomes in clinical settings. However, rigorous 471 randomized clinical trials are needed to further validate these findings. Additionally, further 472 investigation is required to determine the optimal type and dosage of senolytics in combination 473 with ICIs. 474

In summary, this study provides valuable insights into the variability of the tumor immune microenvironment (TIME) across individuals and highlights the potential for enhancing antitumor efficacy by targeting immunosenescence within the TIME. These findings offer a promising avenue for improving outcomes in patients with HNSCC.

479

#### 480 **References**

- Cramer, J. D., Burtness, B. & Ferris, R. L. Immunotherapy for head and neck cancer: Recent advances and
   future directions. *Oral Oncology* 99, 104460 (2019).
- 483
  2. Bernier, J. *et al.* Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced
  484
  484 Head and Neck Cancer. *The New England Journal of Medicine* (2004).

- 485 3. Cooper, J. S. *et al.* Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell
  486 Carcinoma of the Head and Neck. *N Engl J Med* 350, 1937–1944 (2004).
- 487
  4. Puram, S. V. *et al.* Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head
  488
  488 and Neck Cancer. *Cell* **171**, 1611-1624.e24 (2017).
- 489 5. Li, J. *et al.* Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair490 deficient colorectal cancer. *Cancer Cell* 41, 1152-1169.e7 (2023).
- 491 6. Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. *Nat Rev Cancer* 23,
  492 295–316 (2023).
- 493
  7. Bhatia, A. & Kumar, Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive
  494 review. *Expert Review of Clinical Immunology* 10, 41–62 (2014).
- 495 8. Tumeh, P. C. *et al.* PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 515,
  496 568–571 (2014).
- 497 9. Galon, J. *et al.* Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *The*498 *Journal of Pathology* 232, 199–209 (2014).
- 499 10. Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: impact
  500 on clinical outcome. *Nat Rev Cancer* 12, 298–306 (2012).
- 501 11. Yousefzadeh, M. J. *et al.* An aged immune system drives senescence and ageing of solid organs. *Nature* 594,
  502 100–105 (2021).
- 503 12. Goronzy, J. J. & Weyand, C. M. Understanding immunosenescence to improve responses to vaccines. *Nat* 504 *Immunol* 14, 428–436 (2013).
- 505 13. Liu, Z. *et al.* Immunosenescence: molecular mechanisms and diseases. *Sig Transduct Target Ther* 8, 200
  506 (2023).
- 507 14. Zinatizadeh, M. R. *et al.* Immunosenescence and inflamm-ageing in COVID-19. *Ageing Research Reviews* 84,
  508 101818 (2023).
- Ferrara, R. *et al.* Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer
   Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. *Clinical Cancer Research* 27, 492–503 (2021).
- 512 16. Lian, J., Yue, Y., Yu, W. & Zhang, Y. Immunosenescence: a key player in cancer development. *J Hematol*513 *Oncol* 13, 151 (2020).

- 514 17. Liu, X. *et al.* Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor
- 515 immunity and immunotherapy. *J Immunother Cancer* **10**, e005020 (2022).
- 516 18. Park, M. D. *et al.* Hematopoietic aging promotes cancer by fueling IL-1<sup>II</sup>-driven emergency myelopoiesis.
   517 *Science* eadn0327 (2024) doi:10.1126/science.adn0327.
- 518 19. Vicente, R., Mausset-Bonnefont, A.-L., Jorgensen, C., Louis-Plence, P. & Brondello, J.-M. Cellular senescence
  519 impact on immune cell fate and function. *Aging Cell* 15, 400–406 (2016).
- 520 20. Pinti, M. *et al.* Aging of the immune system focus on inflammation and vaccination. (2017).
- 521 21. Mittelbrunn, M. & Kroemer, G. Hallmarks of T cell aging. *Nat Immunol* 22, 687–698 (2021).
- 522 22. López-Otín, C. Hallmarks of aging: An expanding universe.
- 523 23. Swanton, C. *et al.* Embracing cancer complexity: Hallmarks of systemic disease. *Cell* **187**, 1589–1616 (2024).
- 524 24. Luo, O. J. *et al.* Multidimensional single-cell analysis of human peripheral blood reveals characteristic features
  525 of the immune system landscape in aging and frailty. *Nat Aging* 2, 348–364 (2022).
- 526 25. Weivoda, M. M. *et al.* Identification of osteoclast-osteoblast coupling factors in humans reveals links between
  527 bone and energy metabolism. *Nat Commun* 11, 87 (2020).
- 528 26. Zhang, Y. *et al.* Single-cell analyses reveal key immune cell subsets associated with response to PD-L1
  529 blockade in triple-negative breast cancer. *Cancer Cell* **39**, 1578-1593.e8 (2021).
- 530 27. Marta, G. N. *et al.* Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral
   531 cavity cancer patients: Systematic review and meta-analysis. *Eur J Cancer* **51**, 2596–2603 (2015).
- 532 28. Liu, J. *et al.* Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic
  533 Disease. *Cancer Discov* 6, 1382–1399 (2016).
- D, W. *et al.* Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in
   resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. *Nature communications* 15, (2024).
- 537 30. Sharma, P. & Allison, J. P. Dissecting the mechanisms of immune checkpoint therapy. *Nat Rev Immunol* 20,
  538 75–76 (2020).
- 539 31. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell
  540 response. *Nat Rev Immunol* 12, 269–281 (2012).
- 541 32. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. *Science* **348**, 56–61 (2015).

542	33. Bagchi, S., Yuan, R. & Engleman, E. G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical
543	Impact and Mechanisms of Response and Resistance. Annu. Rev. Pathol. Mech. Dis. 16, 223–249 (2021).

- Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to
  immune checkpoint blockade. *Cell* 184. 5309–5337 (2021).
- 546 35. De Miguel, M. & Calvo, E. Clinical Challenges of Immune Checkpoint Inhibitors. *Cancer Cell* 38, 326–333
  547 (2020).
- 548 36. Im, S. J. *et al.* Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature* 537, 417–
  549 421 (2016).
- Siddiqui, I. *et al.* Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in
   Response to Vaccination and Checkpoint Blockade Immunotherapy. *Immunity* 50, 195-211.e10 (2019).
- 38. Utzschneider, D. T. *et al.* T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune
   Response to Chronic Viral Infections. *Immunity* 45, 415–427 (2016).
- 39. Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint Immunotherapy in
   Melanoma. *Cell* 175, 998-1013.e20 (2018).
- 40. Li, H. *et al.* Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within
  Human Melanoma. *Cell* 176, 775-789.e18 (2019).
- 41. Van Der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights
  from single-cell analysis. *Nat Rev Cancer* 20, 218–232 (2020).
- 560 42. Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. *Cancer Cell* **33**, 547–562 (2018).
- 43. Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. *Nat Rev Immunol* 22, 209–
  223 (2022).
- 563 44. Baker, D. J. *et al.* Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. *Nature* 530, 184–189
  564 (2016).
- 565 45. Xu, M. *et al.* Senolytics improve physical function and increase lifespan in old age. *Nat Med* 24, 1246–1256
  566 (2018).
- 567 46. Saul, D. *et al.* A new gene set identifies senescent cells and predicts senescence-associated pathways across
  568 tissues. *Nat Commun* 13, 4827 (2022).
- 569 47. Huang, K. *et al.* AgeAnno: a knowledgebase of single-cell annotation of aging in human. *Nucleic Acids*570 *Research* 51, D805–D815 (2023).

- 571 48. Chang, J. *et al.* Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat* 572 *Med* 22, 78–83 (2016).
- 49. Liu, H. *et al.* Rutin is a potent senomorphic agent to target senescent cells and can improve chemotherapeutic
  efficacy. *Aging Cell* 23, e13921 (2024).
- 575 50. Schafer, M. J. *et al.* Cellular senescence mediates fibrotic pulmonary disease. *Nat Commun* **8**, 14532 (2017).
- 576 51. Farr, J. N. *et al.* Targeting cellular senescence prevents age-related bone loss in mice. *Nat Med* 23, 1072–1079
  577 (2017).
- 578 52. Zhang, P. *et al.* Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and
   579 cognitive deficits in an Alzheimer's disease model. *Nat Neurosci* 22, 719–728 (2019).
- 580 53. Novais, E. J. *et al.* Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age581 dependent intervertebral disc degeneration in mice. *Nat Commun* 12, 5213 (2021).
- 54. Hickson, L. J. *et al.* Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of
  Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine* 47, 446–456 (2019).
- 55. Justice, J. N. *et al.* Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot
   study. *EBioMedicine* 40, 554–563 (2019).
- 586 56. Jd, S. *et al.* Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell
   587 Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. *JAMA oncology* 6, (2020).
- 57. R, U. *et al.* Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human
  Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research* 26, (2020).
- 58. Wise-Draper, T. M. *et al.* Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable
  Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res* 28, 1345–1352
  (2022).
- 59. Zinner, R. *et al.* 968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in
   595 HPV(-) resectable locally advanced head and neck cancer. *Annals of Oncology* **31**, S682 (2020).
- 596 60. Ce, H. *et al.* Adjuvant immunotherapy: the sting in the tail. *European journal of cancer (Oxford, England*□:
  597 1990) 132, (2020).

25

598	61.	Soto-Heredero, G., Gómez de Las Heras, M. M., Escrig-Larena, J. I. & Mittelbrunn, M. Extremely
599		Differentiated T Cell Subsets Contribute to Tissue Deterioration During Aging. Annu Rev Immunol 41, 181-
600		205 (2023).
601	62.	Cao, W. et al. TRIB2 safeguards naive T cell homeostasis during aging. Cell Rep 42, 112195 (2023).
602	63.	Sharma, S. et al. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells:
603		implications for T-cell immunotherapy. J Immunother Cancer 11, e006267 (2023).
604	64.	Czystowska, M. et al. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates
605		with disease recurrence in patients with HNSCC. Clin Cancer Res 19, 889-899 (2013).
606		
607		

- 608 Methods:
- 609

#### 610 Human specimens

This study includes three independent clinical trials for HNSCC: OOC-001 (NCT04718415), 611 REDUCTION-I (NCT05582265), and COIS-01 (NCT05724329). Eligible HNSCC patients 612 613 received prior approval from the Institutional Review Board (IRB) at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, and were required to provide written informed consent to 614 participate in the study. All patients were diagnosed with HNSCC by expert histopathologists, 615 616 and all invasive procedures and systemic treatments were ordered by the patients' attending 617 physicians, individually determined based on the response after the administration of pharmacological drugs. The eight patients used for the scRNA-Seq study were part of the OOC-618 001 clinical trial and received the described treatment regimen. Specifically, all patients had their 619 620 primary tumor tissue and peripheral blood collected through biopsy at the time of enrollment, and the peripheral blood was collected after sintilimab in combination with carboplatin and nab-621 paclitaxel treatment before surgery. Among the 7 patients (SH1-SH7) who underwent surgery, 3 622

623 patients are MPR, and 4 patients are noMPR. Paired biopsy samples of primary tumor tissue and peripheral blood were collected at baseline before treatment, and peripheral blood samples were 624 collected 3 weeks after the first dosing cycle. Except for SH1, peripheral blood samples were 625 collected from the other patients before and after the first medication cycle for matching. For 626 patient SH1, blood samples were collected only before the first medication cycle. Peripheral 627 628 blood samples were collected after the second medication cycle for SH1, SH2, SH3, and SH4, and peripheral blood samples were collected for SH3, SH4, and SH7 after the third medication 629 cycle. Paraffin sections from two ongoing clinical study patient cohorts were used for 630 631 immunofluorescence staining of senescent markers P16 and P21. This included 33 MPR patients and 17 noMPR patients from OOC-001, as well as 37 MPR patients and 24 noMPR patients 632 from REDUCTION-I. Another set from COIS-01 collected paraffin sections from 7 patients for 633 634 immunofluorescence staining before and after treatment.

635

#### 5 Sample collection and processing

Peripheral blood mononuclear cells (PBMCs) were isolated according to the manufacturer's protocol. Briefly, before the start of treatment, 5 mL of fresh peripheral blood was collected in EDTA anticoagulated tubes and subsequently extracted with Lymphoprep<sup>TM</sup> (Stem Cells) solution. After centrifugation, carefully transfer lymphocytes to a new 50 mL tube and wash with PBS. Next, incubate the lymphocytes for 10 minutes to lyse the blood cells. Finally, cells were resuspended in sorting buffer containing PBS plus 2% FBS.

For tumor biopsy samples, cut tissue with a diameter of about 5 mm at the junction of the tumor and normal tissue as a representative sample. All 7 tumor biopsy samples were collected as a discovery cohort through routine clinical practice and then stored in MACS Tissue Storage Solution (Miltenyi). Fresh biopsy samples of oral HNSCC were minced and isolated using a human tumor isolation kit (Miltenyi), followed by enzymatic digestion on a rotor at 37°C for 45–

60 min. The detached cells were then passed through 70 µm and 40 µm cell filters (Biosharp) 647 and centrifuged at  $300 \times g$  for 10 min. Pelleted cells were suspended in red blood cell lysis buffer 648 (Thermo-Fisher) and incubated on ice for 2 min, then washed and resuspended in phosphate 649 buffer supplemented with 2% fetal bovine serum (FBS, ExCell) PBS twice in saline (PBS, 650 Gibco). The viability of all samples was confirmed to be >90% using the trypan blue (Thermo-651 Fisher) exclusion method. 652

#### 653

#### Single-cell RNA-seq library and TCR-seq library preparation and sequencing

According to the manufacturer's protocol, scRNA-seq libraries were constructed. In 654 summary, the density of cells was determined after washing once with PBS containing 0.04% 655 bovine serum albumin (BSA. Invitrogen). Next,  $2 \times 10^5$  cells were loaded on a 10x Genomics 656 GemCode Single cell instrument (10x Genomics) that generates single-cell Gel Bead-In-657 EMulsion (GEMs). Libraries were generated and sequenced from the cDNAs with the 658 Chromium Next GEM Automated Single Cell 3' cDNA Kitv3.1 (10x Genomics). Upon 659 dissolution of the Gel Bead in a GEM, primers were released and mixed with cell lysate and 660 Master Mix. Barcoded, full length cDNAs were then reverse-transcribed from polyadenylated 661 mRNA. Full-length, barcoded cDNAs were then amplified by quantitative real-time PCR 662 (qRT PCR) for library construction. Finally, single-cell RNA libraries were sequenced by an 663 Illumina HiSeq X Ten sequencer with 150 bp paired-end reads. 664

After reverse transcription and cell barcoding, the cDNA was de-emulsified and purified 665 using silane magnetic beads, followed by PCR amplification. The amplified cDNA was then 666 used for 5' gene expression library construction and TCR V(D)J targeted enrichment 667 amplification using the Illumina® bridge. Libraries prepared according to the manufacturer's 668 user guide were then purified and analyzed for quality assessment. Single-cell RNA and TCR 669

670 V(D)J libraries were sequenced by an Illumina HiSeq X Ten sequencer using 150 bp paired-end reads.

- 671

#### **Bulk TCR-seq library preparation and sequencing** 672

Whole Blood Samples Blood was collected in EDTA tubes and sent to isolated PBMCs, and 673 DNA was extracted for TCR $\beta$  analysis by immunoSEQ<sup>65</sup>. Briefly, extracted genomic DNA was 674 amplified using a bias-controlled multiplex PCR system, followed by high-throughput 675 sequencing. Raw data processing and analysis were performed by immunoSEO. Subsequently, 676 we used the International ImMunoGeneTics Information System (IMGT; http://imgt.cines.fr) 677 database for comparison. After the alignment, the relative abundance of each TCR $\beta$  CDR3 678 sequence was clarified and calculated. Furthermore, we use batch correction to eliminate batch 679 effects across different datasets. Subsequently, multiple TCR data statistics were performed. 680

681

### **Bulk ATAC and RNA isolation and sequencing**

Isolation, library construction and sequencing of bulk ATAC and RNA were performed at 682 Gene Denovo Biotechnology Co. (Guangzhou, China). For ATAC sequencing, CD4 naïve cells 683 from C57 mouse tongue tumors were extracted. Tn5 transposase was added to the nuclear 684 suspension. After the reaction was completed, the DNA fragment was purified; the amplified 685 product was then used for PCR amplification. The fragments were purified using AMPure XP 686 magnetic beads (Beckman Coulter, Brea, CA, USA) to construct a sequencing library. After the 687 library construction was completed, Agilent 2100 (Agilent, Santa Clara, CA) was used to detect 688 689 the quality of the library. Libraries that pass the quality inspection will be used for on-machine sequencing (Novaseq 6000) to obtain sequence information of the open chromatin region 690 fragments to be tested. 691

Extraction of CD4 naïve cells from C57 mouse tongue tumors. Total RNA was extracted 692 using Trizol reagent kit (Invitrogen) according to the manufacturer's protocol. RNA quality was 693

assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies). After total RNA was extracted,
eukaryotic mRNA was enriched by Oligo(dT) beads. Then the enriched mRNA was reversely
transcribed into cDNA by using NEBNext Ultra RNA Library Prep Kit for Illumina (NEB #7530,
New England Biolabs). The resulting cDNA library was sequenced using Illumina Novaseq6000
by Gene Denovo Biotechnology Co. (Guangzhou, China).

699 scRNA-Seq data processing

The Cell Ranger toolkit (version 3.1.0) provided by 10x Genomics was applied to aggregate 700 701 raw data, filter low-quality reads, align reads to the human reference genome (GRCh38), assign cell barcodes and generate a UMI matrix. The toolkit Scanpy (version 1.9.3)<sup>66</sup> was used to 702 analyze single-cell RNA sequencing (scRNA-Seq) data. Specifically, the original UMI matrix 703 was processed to filter out genes expressed in less than 10 cells and cells with less than 200 704 705 genes. We further quantified the number of genes and UMI counts per cell and maintained thresholds for high-quality cells of 1000-50,000 UMIs, 400-6,000 genes and less than 10% 706 mitochondrial gene counts, ensuring that most heterogeneous cell types were Incorporate into 707 downstream analyses. Scrublet (version 0.2.3)<sup>67</sup> was then applied to each sequencing library to 708 remove potential doublets, using default parameters. The normalized expression matrix was 709 710 calculated from raw UMI counts normalized to total counts per cell (library size) and then scaled by 1e4 and log-transformed. 711

### 712 Dimensionality reduction and unsupervised clustering of scRNA-seq data

Dimensionality reduction and unsupervised clustering were performed according to standard workflows in Scanpy <sup>66</sup>. Briefly, use highly variable genes (HVG) based on the highly\_variable\_genes default parameters. Unwanted sources of variation, including total counts, and mitochondrial gene counts were further regressed from the normalized expression matrix. Primary component analysis (PCA) was performed on the variable gene matrix to reduce noise

718 and the top 50 components were used for downstream analysis. To correct for batch effects across different patients, we applied BBKNN to generate a batch-balanced k-nearest neighbor 719 (KNN) map, which identifies the top neighbors of each cell in each batch individually, rather 720 than the entire pool of cells  $^{67}$ . The Leiden algorithm is then applied to such nearest neighbor 721 graphs to detect communities and find cell clusters <sup>68</sup>. It is worth noting that the same principal 722 components are also used for nonlinear dimensionality reduction to generate uniform 723 distributions for visualization in Uniform Manifold Approximation and Projection (UMAP). 724 After the first round of unsupervised clustering, we annotated each cell cluster according to 725 726 canonical immune cell markers and identified the main immune cell types, including T cells, NK 727 cells, B cells, myeloid cells, fibroblasts, endothelial cells and tumor cells. Use the rank genes groups function with parameter method Wilcoxon to detect marker gene. 728

729 **TCR sequences assembly** 

Applying the TCR sequence assembly Cell Ranger toolkit (version 3.1.0) provided by 10x

Genomics will perform FASTQ sequence quality filtering, sequence alignment, V(D)J assembly

and TCRαβ pairing. Only TCRs containing paired TRAV-CDR3-TRAJ and TRBV-CDR3-

733 TRBJ-TRBC chains were considered valid and retained for downstream analysis. Each cell is

assigned a pair of  $\alpha$  and  $\beta$  chains with the highest UMI count. Cells with identical TCR pairs are

defined as clonal and are thought to originate from a common ancestor.

736 Calculation of Diversity Index

Characterize the immune repertoire by examining diversity and clonality. Immune
 repertoire analysis involves a variety of diversity indices, such as Chao1 index, Clone Diversity
 Index, Richness index and Shannon index <sup>24</sup>.

740 Bulk RNA-sequencing and ATAC-sequencing data processing

31

741	For bulk RNA-Seq data, reads were filtered using FASTQ (0.23.3) default parameters, and
742	then clean reads were aligned to the mouse genome GRCm39 and gencode. vM30 annotations
743	were using STAR (2.7.10b) and using RSEM (1.3.1) rsem-calculate-expression is in quantitative
744	analysis of gene expression. Difference analysis was done using DESeq2 (1.42.0).
745	For bulk ATAC data, use FASTQ (0.23.3) for quality control, then use bwa (0.7.17) to align
746	the reads to the reference genome (GRCm39), and peak using Genrich (0.6.1, https://github.com
747	/jsh58/Genrich). Peak is annotated to gencode. vM30 through annotatePeaks.pl of HOMER
748	(4.11). The difference peak is obtained by BEDTools (v2.31.1) subtract.

749 (<u>https://github.com/jsh58/ATAC-seq2</u>)

#### 750 Generation of Immunosenescence gene set

Our own senescence-related gene set was generated by combining genes reported to be 751 enriched in senescent immune cells in previous studies and experimentally validated in at least 752 human or mouse cells. We screened 1745 studies, but after removing studies reporting duplicates, 753 case reports, non-human genes, and non-high-throughput sequencing, a list of 6 studies was 754 developed (Senmayo <sup>46</sup>, GSE157007 <sup>24</sup>, HRA000624 <sup>69</sup>, HRA000395 <sup>70</sup>, HRA000615 <sup>71</sup> and 755 HSA000203<sup>72</sup> and 1 database (https://genomics.senescence.info/cells/)). We screen immune 756 cells and compare samples from young and old people to obtain differential genes that are highly 757 expressed in the elderly, remove duplicate genes, and screen genes that appear in at least two 758 data sets. Based on the enrichment of relevant gene pathways and machines Learning method, 759 154 genes constituting the immunosenescence gene set were identified (Supplementary Table 6). 760

761

GO enrichment analysis and Gene set enrichment analysis (GSEA)

Using the R package ClusterProfiler (version 4.8.3), gene function annotation and GO were performed on genes that were down-regulated and up-regulated in T cells and B cells in the MPR and noMPR groups, as well as differential genes between macrophages and monocytes and other

765 cells. Analysis, a program that supports statistical analysis and visualization of functional
 766 profiles of genes and gene clusters.

- GSEA was performed by the GSEA software
   (http://software.broadinstitute.org/gsea/index.jsp)
   Gene sets used in this article were
   c2.cp.kegg.v6.2.symbols.gmt downloaded from the Molecular Signatures Database (MSigDB,
   http:// software.broadinstitute.org/gsea/msigdb/index.jsp).
- 771 Gene Set Score Analysis

The scoregenes function in Scanpy is used to calculate the module score of a gene expression program in a single cell. First, all analyzed genes were binned according to their average expression, and control genes were randomly selected from each bin. Then, the average expression value of the gene set at the single-cell level minus the aggregate expression of the control gene set was calculated. The gene set was obtained from the immunosenescence gene set constructed by ourselves. The genes in each gene set are listed in Supplementary Table 6.

778 Cell-cell interaction

We used the CellChat package (1.6.1), which allows analysis of scRNA-Seq data. We
studied the interaction between immune cells (i.e. T cells and B cells) and myeloid cells (i.e.
macrophages and monocytes), one of which contributes ligands or receptors during the
interaction, using CellChat Signaling pathway networks are analyzed and visualized.

783 Trajectory inference of immune cell subsets across tissues

The status of immune cell subpopulations in the periphery and in tumors is dynamic, and they may differentiate into different cell states and exert different biological functions in different patients. We use the pseudo-temporal inference algorithm Monocle 2 for trajectory analysis to reconstruct the cell differentiation trajectory of immune cells across tissues, reveal the

33

progression of cells and reconstruct the trajectory of cells progressing through biological
 processes under study.

790 Survival analysis

Survival analysis uses TCGA and HNSCC data to evaluate the prognostic performance of 791 different immune cell populations. Gene expression data and clinical information of HNSCC 792 patients were downloaded from cBioPortal (https://www.cbioportal.org/study/clinicalData). Use 793 Cibersort and Xcell to extract T cells and B cells subtypes and group them based on the 794 expression levels of characteristic genes. Specifically, HNSCC patients were divided into four 795 groups based on the median proportion of immune cell subsets and the median mean expression 796 797 of a given signature gene. In the analysis of myeloid cells, a subset of cells within a single cell is characterized using a set of signature genes, defined based on a combination of typical marker 798 799 genes for major immune cell types and cluster-specific marker genes. Specifically, for different macrophage clusters, we used the typical IGF1<sup>+</sup> M $\phi$  marker genes "CD276", "APOE", "TREM2", 800 "HTRA1", "PTGR1", "RBP1", "IGF1", "CDKN1A", "CD81" define its signature. HNSCC 801 802 patients were divided into two groups based on the median of the mean expression of the given signature. Survival analysis was performed using the COX proportional hazards model 803 implemented in the R package "survival". 804

805 Hierarchical Clustering

In the end, cell subpopulations and characteristic genes were used to construct a neoadjuvant treatment model for patients before surgery, and a hierarchical clustering method was used to create groups. Cophenetic distance was used to evaluate the objects in the group so that they were like each other and different from objects in other groups. Verify different cell subpopulations and gene signatures to evaluate the efficacy of neoadjuvant therapy in patients before surgery.

### 812 TNBC single cell RNA sequencing data processing

TNBC single-cell RNA sequencing data comes from GSE169246. Patients who received 813 combined neoadjuvant chemotherapy and immune therapy before surgery were screened, and the 814 patients were divided into PR (response) and SD (non-response) groups based on the 815 corresponding imaging conditions. The rest of the analysis process as before, similar cell 816 subpopulations were evaluated after dimensionality reduction clustering, and senescent immune 817 cells were evaluated on the cell subpopulations. Hierarchical clustering was used to verify the 818 819 effect of different cell subpopulations and gene characteristics on patients receiving neoadjuvant 820 therapy before surgery to evaluate.

#### 821 Animal experiments.

The animal experiments in this study were conducted with the approval of the Animal Ethics Committee of Sun Yat-sen University and the Institutional Animal Care and Use Committee at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS). For all animal experiments, mice were housed under controlled conditions of ~50% humidity, ~25 °C temperature and a 12h light/dark cycle. Isoflurane was used for anaesthesia. At the end of all experiments, animals were euthanized under CO<sub>2</sub> anaesthesia.

828

#### 4-NQO-induced mouse HNSCC model.

Female C57 mice (12 months old) were housed and drinking water containing 50 mg/L 4NQO was given for 12 weeks. All diet and water were made available ad libitum. Subsequently,
the oral cavities of the mice were examined. 24 mice with lesions were randomly divided into 4
groups. Normal drinking water was given. Two days later, αPD-1 was administered
intraperitoneally at a dosage of 10 mg/kg. Then, mice were euthanized. Tongues were collected
for pathological examination and IF.

835 **Establishment of cell lines and tissue culture.** 

Female C57 mice (6-8 weeks old, weighing 18-20 g) were obtained from Gempharmatech (Guangdong, China). 4-nitroquinoline 1-oxide (4-NQO) was diluted in drinking water to a final concentration of 50 mg/L for the animals, with weekly replacements. After 12 weeks, all animals were returned to normal water until week 28. At week 28, animals were euthanized for tissue extraction. Lesions were dissected, and cells were isolated to establish the 4MOC cell line.

841 SA-β-gal staining

Fresh tissues were fixed in 10% neutral buffered formalin (NBF) for 3–4 h and then transferred to 30% sucrose overnight. Tissues were then embedded in cryo-embedding medium (OCT) and cryosectioned at 5 µm for staining of SA-β-gal (pH 6.0) at 37  $\square$  °C for 16–24 h in SAβ-gal staining solution (40 mM citric acid in sodium phosphate buffer, 5 mM K<sub>4</sub>[Fe(CN)<sub>6</sub>]3H<sub>2</sub>O, 5 mM K<sub>3</sub>[Fe(CN)<sub>6</sub>], 150 mM sodium chloride, 2 mM magnesium chloride and 1 mg ml<sup>-1</sup> X-gal dissolved in *N*,*N*-dimethylformamide). Slides were imaged at 20× with a Panoptiq slide scanner (ViewSiq).

## 849 **RNA isolation and qRT–PCR**

Tissues were collected from euthanized mice and flash-frozen in liquid nitrogen. Tissues 850 were homogenized using FastPrep-24 homogenizer (MP Biomedicals) and total RNA was 851 isolated by Trizol extraction according to manufacturer's specifications (Thermo Fisher). Total 852 RNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher) and 1 µg of total 853 RNA used to generate cDNA via the Transcriptor First Strand cDNA synthesis kit (Roche) 854 according to the manufacturer's specifications. Gene expression changes in (Cdkn2a)  $p16^{lnk4a}$ , 855 (Cdkn1a)  $p21^{Cip1}$  were quantified by qRT-PCR reactions using 20 µl reaction volumes and a 856 StepOne thermocycler (Thermo Fisher) with input of 50 ng total RNA per reaction. For each 857 858 sample, reactions were performed in duplicate. Data were analysed by the  $\Delta\Delta$ Ct method and expression was normalized to Gapdh. 859
### 860 **Quantitation of 8-OHdG DNA lesions**

861 Tissues from mice were analysed for 8-OHdG levels using the ELISA kit (Abcam) 862 according to manufacturer's specifications.

863 **Immunoblotting** 

Snap-frozen livers from mice were incubated in RIPA buffer (Thermo-Fisher) on ice for 30 864 min after being homogenized with a FastPrep-24 homogenizer. Samples were centrifuged at 865 17,000g for 15 min at  $4 \square$  °C. Supernatant was resuspended in 2× SDS loading buffer and 50 µg 866 of total protein run on a 4-15% SDS-PAGE gel (Bio-Rad) before being transferred to 867 nitrocellulose membrane. Membranes were blocked for 1 h in 10% milk TBS-T solution at room 868 temperature before incubation in anti-yH2AX (Novus Biologicals, NB100-384, 1:2,000) and 869 anti-GAPDH (Abcam, ab8425, 1:5,000) antibody at 4<sup>°</sup>C overnight. After washing, samples 870 871 were incubated in either horse anti-mouse HRP (Cell Signaling Technology, 7076S) or goat antirabbit HRP secondary antibody (Thermo-Fisher, 656120, 1:2,000) in 5% milk TBS-T solution 872 for 3 h before washing and visualization with ECL (Thermo-Fisher). 873

874

# TIL isolation and flow cytometry

Tumors were dissected, minced, and resuspended in complete media (DMEM with 10% 875 FBS and 1% antibiotics) supplemented with Collagenase-D (1 mg/mL; Roche) and incubated at 876 37 °C for 30 min with shaking to form a single-cell suspension. Tissue suspensions were washed 877 with fresh media and passed through a 100-µm strainer. Samples were washed with PBS and 878 879 immediately processed for live/dead cell discrimination using BD HorizonTM Fixable Viability Stain 510. Cell surface staining was done for 30 min at 4 °C with the following antibodies: CD45 880 (30-F11) (1:100), CD3 (145-2C11) (1:400), CD8a (53-6.7) (1:100), CD4 (RM4-4) (1:400), 881 882 NK1.1 (PK136) (1:400), CD62L (MEL-14) (1:200) and CD44 (IM7) (1:100). All flow cytometry

data acquisition was done using Beckman Cytexpert and analyzed using FlowJo software(v10.8.1).

- (10.0.1):
- 885 Immunofluorescence and image quantification

Briefly, tissues were harvested, fixed, and paraffin embedded. Slides were stained for P16, P21, CD4, CD8a, CCR7, PAN-CK, LCK, CD62L and S100A11 antibodies (Supplementary Materials). Quantification of immune infiltration was done using QuPath, an open-source software for digital pathology image analysis. For the quantification, at least three regions of interest (ROI) were selected for each condition and the percentage of positive cells was calculated.

892 **DNA sequencing and genomic signature analysis** 

Raw sequencing data were aligned to the mm10 reference genome using BWA. Somatic 893 894 mutations were identified by comparing the sequencing data from each cancer sample to the sequencing data from a normal tissue derived from the tail of one of the mice (all mice were 895 genetically identical). To ensure robustness of the results, a consensus variant calling strategy 896 was leveraged in which somatic mutations were identified using three independent 897 bioinformatics tools: Strelka2, Varscan2, and GATK4 Mutect2. Somatic mutational profiles 898 were derived using the immediate sequencing context by evaluating the base 5' and the base 3' to 899 900 each single point mutation.

901

902 **Data availability** 

All data associated with this study are present in the paper or the Supplementary Materials. The raw sequence data including single-cell sequencing, TCR/BCR sequencing of human, as well as RNA and ATAC sequencing of CD4 naïve T cells datasets generated and analyzed

906	during	g the current study have been deposited in Genome Sequence Archive (Genomics,
907	Protec	omics & Bioinformatics 2021) with accession code PRJCA027702 and PRJCA028161.
908		
909	Meth	ods References
910	65.	Nolan, S. et al. A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations
911	from na	atural and synthetic exposure to SARS-CoV-2. Preprint at https://doi.org/10.21203/rs.3.rs-51964/v1 (2020).
912	66.	Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis.
913	Genom	<i>e Biol</i> <b>19</b> , 15 (2018).
914	67.	Polański, K. et al. BBKNN: fast batch alignment of single cell transcriptomes. Bioinformatics 36, 964–965
915	(2020).	
916	68.	Traag, V. A., Waltman, L. & Van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected
917	commu	unities. Sci Rep 9, 5233 (2019).
918	69.	Huang, Z. et al. Effects of sex and aging on the immune cell landscape as assessed by single-cell
919	transcri	iptomic analysis. Proc. Natl. Acad. Sci. U.S.A. 118, e2023216118 (2021).
920	70.	Zou, Z. et al. A Single-Cell Transcriptomic Atlas of Human Skin Aging. Developmental Cell 56, 383-
921	397.e8	(2021).
922	71.	Wang, S. et al. A single-cell transcriptomic landscape of the lungs of patients with COVID-19. Nat Cell
923	Biol <b>23</b>	, 1314–1328 (2021).
924	72.	Zheng, Y. et al. A human circulating immune cell landscape in aging and COVID-19. Protein Cell 11,
925	740–77	70 (2020).
926	73.	Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting
927	genome	e-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545–15550 (2005).
928		
929		
930		
931		

Acknowledgments: We thank all patients and their families for participation during sample 932 collection. We are grateful to the support of the Clinical Research Design Division and Clinical 933 Research Center at Sun Yat-sen Memorial Hospital, Sun Yat-sen University. The co-author Dr. 934 Soldano Ferrone sadly passed away on January 10, 2023, at the age of 82, after an 8-week-long 935 battle with COVID-19. He was the supervisor of Dr. Song Fan during Dr. Fan's post-doctoral 936 work in his lab at Massachusetts General Hospital (MGH). Due to his constantly invaluable 937 guidance and suggestions, which greatly helped improve and organize this study, all contributing 938 authors agree to keep him as a co-author of this manuscript. We thank all the members of the Fan 939 lab for valuable discussions and help with experimental techniques and analysis of the 940 manuscript. This work was supported by the Joint Funds of the National Natural Science 941 Foundation of China (U21A20381), the General Funds of the National Natural Science 942 943 Foundation of China (82373452), the Guangdong Natural Science Funds for Distinguished Young Scholar (2022B1515020061), the Guangdong Basic and Applied Basic Research 944 Foundation (2021A1515220138), the Guangzhou Basic Research Program Jointly Funded by 945 Municipal Schools (Institutes) (202201020367), the Fundamental Research Funds for the Central 946 Universities, Sun Yat-sen University (16ykpy10), the Fundamental Research Funds for the 947 Central Universities, Sun Yat-sen University (19ykzd20), the General Funds of the National 948 Natural Science Foundation of China (32071451), the Guangdong Provincial Pearl River Talents 949 Program (2021QN02Y747), Shenzhen Science Technology the and Program 950 (RCYX20210706092100003), and by the Shenzhen Medical Research Funds grant (A2303005). 951

952

Author contributions: X.W., S.F., X.F., F.X., N.L., J.W. and E.D. designed the study and
wrote the manuscript, S.F., X.F., F.X. and X.W. supervised the study. Single-cell RNA and

959	Competing interests: The authors declare that they have no competing interests.
958	and interpreted the data. All authors critically revised the paper.
957	patient samples and analyzed clinical data. S.F., N.L., J.W. and E.D. performed experiments
956	by N.L., J.W., E.D., T.C, Q.L. and J.Z., B.W., J.W., E.D., X.D., S.F., T.C and Y.Z. collected
955	T/BCR sequencing, RNA-Seq and ATAC-Seq involves library preparation and data analysis

1	<b>Reversing Immunosenescence with Senolytics to Enhance Tumor</b>
2	Immunotherapy
3	Niu Liu <sup>1,2,3#</sup> , Jiaying Wu <sup>1,2#</sup> , Enze Deng <sup>4,5#</sup> , Jianglong Zhong <sup>1,2#</sup> , Bin Wei <sup>1,2#</sup> , Tingting Cai <sup>1,2#</sup> ,
4	Xiaohui Duan <sup>6</sup> , Sha Fu <sup>7</sup> , David O. Osei-Hwedieh <sup>8</sup> , Ou Sha <sup>9</sup> , Yunsheng Chen <sup>1,2,3</sup> , Xiaobin Lv <sup>10</sup> ,
5	Yingying Zhu <sup>11</sup> , Lizao Zhang <sup>1,2</sup> , Hsinyu Lin <sup>1,2</sup> , Qunxing Li <sup>1,2</sup> , Peichia Lu <sup>1,2</sup> , Jiahao Miao <sup>1,2,3</sup> ,
6	Teppei Yamada <sup>12</sup> , Lei Cai <sup>13</sup> , Hongwei Du <sup>14</sup> , Sylvan C. Baca <sup>8</sup> , Qingpei Huang <sup>4</sup> , Soldano Ferrone <sup>†</sup>
7	, Xinhui Wang <sup>15*</sup> , Fang Xu <sup>3,16,17*</sup> , Xiaoying Fan <sup>4,18*</sup> , Song Fan <sup>1,2*</sup>



# Fig. 1 The results of the Phase II clinical trial (OOC-001) and scRNA-Seq data indicate that MPR patients demonstrate increased diversity in immune response-related cell subtypes and exhibit decreased expression of senescence markers.

12	<b>a</b> , Waterfall plot depicting the treatment response of patients in the HNSCC neoadjuvant clinical
13	trial OOC-001 (NCT04718415, n=50). <b>b</b> , Pie charts depicting radiological and pathological
14	response rates in OOC-001. c, The changes and proportional statistics of TNM staging after
15	treatment for primary tumors in different patients. d, Schematic overview of the experimental
16	design and analytical workflow. e, UMAP plot of the immune cells that passed quality control.
17	Immune cell clusters are annotated and marked by color code. $f$ , Prevalence of each single-cell
18	cluster (column) in all samples $(n = 7)$ from different groupings of tissue (rows). Green dots
19	represent tumors samples, pink dots represent peripheral blood samples of pre-treatment (P0),
20	and red dots represent peripheral blood samples of post-treatment (P1). g, Estimation of size and
21	diversity of TCR repertoires for T cell clusters and BCR repertoires for B cell clusters between
22	MPR and noMPR groups in tumors. The number of TCR and BCR clonotypes estimated by
23	Chao1 (Materials and Methods) illustrates the predicted theoretical clonotype diversity. Data are
24	expressed as mean $\pm$ s.e.m. <b>h</b> , Quantifications of immunofluorescent staining for senescent
25	markers P16 and P21 on paraffin sections from MPR and noMPR patients in two patient cohorts
26	(Cohort1 n=50, Cohort2 n=61). *P $\square < \square 0.05$ , **P $\square < \square 0.01$ , ***P $\square < \square 0.001$ .



28	Fig. 2 Patient responses to immunotherapy are associated with the expression of IAGs in
29	both T and B cell subsets, as well as the interaction of $\mathbf{IGF1}^+$ M $\phi$ with T and B cells.
30	a, The IAGs significantly enriched in all immune cells in peripheral blood of frail elderly people
31	(GSE157007) and old people (PRJCA002856). b, The Ridge plot of IAGs score analysis for
32	major T cells clusters. c, Dot plot of intersection genes of HNSCC T cell DEGs and IAGs
33	between MPR and noMPR groups. d, UMAP of T cells from 4 paired tumor and blood samples
34	(12 samples total), highlighting shared clones between tumors (green) and P0 (pink, pre-
35	treatment blood) and P1 (red, post-treatment blood). e, Shared clonal cells ratio between tumor
36	(green) and P0 (pink, pre-treatment blood) and P1 (red, post-treatment blood) T cells from 4
37	paired tumor and blood samples. f, Paired TCR results Shows the overall number of TCR clones
38	(upper row), and the status of single clones after normalization (lower row). g,
39	Immunohistological staining quantifications of CD4 and S100A11 in HNSCC patients of two
40	cohorts (n=12 per group). h, Low expressions of S100A11 and high proportion of CD4 Naïve T
41	cells and memory B cells were significant associated with better OS. i, Hierarchical clustering
42	tree shows different models distinguish pathological responses of patients following the
43	combination therapy before surgery. T&B cells mean using the proportional distribution of T and
44	B cells and representative genes as a model to predict the patient's response. T cells alone or B
45	cells alone means using the proportional distribution of T cells or B cells and representative
46	genes as a model to predict patient response to treatment (the inner circle is the HNSCC patients'
47	number, and the outer circle is the cophenetic distance result to evaluate the effect). <b>j</b> , The
48	cellular compositions of myeloid cell clusters in P0 and P1 between MPR and noMPR groups in
49	HNSCC. <b>k</b> , Proportion of tumor-infiltrating IGF1 <sup>+</sup> $M\phi$ was inversely correlated to the proportion
50	of tumor infiltrating CCR7 <sup>+</sup> CD4 Naïve T and CD27 <sup>-</sup> Memory B in HNSCC. Pearson correlation
51	(two-sided).



53	Fig. 3 The combination of Dasatinib and Quercetin with $\alpha$ PD-1 enhances therapeutic
54	efficacy in a chemically induced HNSCC mouse model by alleviating immunosenescence.
55	<b>a</b> , Representative images of SA- $\beta$ -gal and eosin staining for senescence markers in tumors and
56	adjacent normal tissues from HNSCC patients, along with paired quantitative analysis of SA- $\beta$ -
57	gal positive areas. Scale bar, 50 $\mu$ m. <b>b</b> , Flowchart for Inducing HNSCC in C57 mice by adding
58	4NQO to drinking water (Top). Schematic representation of different groups in 4NQO-induced
59	mice, including Isotype intraperitoneal injection (Isotype), $\alpha$ PD-1 intraperitoneal injection ( $\alpha$ PD-
60	1), αPD-1+Cisplatin intraperitoneal injection (αPD-1+CP), αPD-1 intraperitoneal injection plus
61	Dasatinib+Quercetin oral gavage ( $\alpha$ PD-1+DQ). Isotype or $\alpha$ PD-1 was administered at 200 µg per
62	mouse, Cisplatin at 3 mg/kg, given on days 0, 7, and 14 of the experiment; Dasatinib (5 mg/kg)
63	and Quercetin (50 mg/kg) were administered on days 0, 3, 7, 10 and 14 (Bottom). c,
64	Immunohistological staining and staining area quantifications of SASP marker P16 and tumor
65	marker Pan-CK in the 4NQO induced HNSCC mice. Scale bar, 10 $\mu$ m. <b>d</b> , Representative images
66	of tongue of mice after receiving Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment. White
67	arrows indicate tumor-like nodules (left); Dysplasia area quantifications of the mice treated with
68	Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ (n= $\Box$ 6 per group) (right). <b>e</b> , Mouse over survival
69	(Surviving mice/Total number of mice x 100%) after receiving Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP or
70	$\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). <b>f</b> , Flow cytometry analysis of the expression of the
71	Senescence marker $\beta$ -gal in immune cells within mouse tumors after receiving Isotype, $\alpha$ PD-1,
72	$\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 5 per group). <b>g</b> , Scatter plot showing the correlation
73	between the expression level of $\beta$ -galactosidase in immune cells and the survival time of mice. <b>h</b> ,
74	Flow cytometry analysis of CD4 <sup>+</sup> , CD8 <sup>+</sup> , and B cell proportions in 4-NQO mouse tumors after
75	receiving Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). <b>i</b> , Expression
76	of senescence markers ( $p16^{Ink4a}$ and $p21^{Cip1}$ mRNA) in CD4 <sup>+</sup> TILs in mouse tumors after

77	receiving Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). <b>j</b> , Flow
78	cytometry analysis of CD4 <sup>+</sup> Naïve T cells proportions in mouse tumors after receiving Isotype,
79	$\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). <b>k</b> , Representative images and
80	quantifications of immunofluorescent staining for CD4 <sup>+</sup> CD62L <sup>+</sup> T cells after receiving Isotype,
81	$\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). The statistical analysis was
82	performed using t test (a), one-way ANOVA (c, d, f, h, i, j, k) and log-rank test (e). P values are
83	shown, and error bars indicate the mean $\pm$ SEM.



85	Fig. 4 Senolytics combined $\alpha$ PD-1 improve the efficacy of solid tumors in <i>Ercc1</i> <sup>+/-</sup>
86	transgenic aging models by reducing SASP and increasing tumor-infiltrating CD4 $^{\scriptscriptstyle +}$ naïve T
87	cells. a, Schematic diagram of orthotopic transplantation of tumor cells derived from the 4-NQO
88	model into the tongues of $Ercc1^{+/-}$ transgenic mice. <b>b</b> , Representative photos of 3-month-old
89	$Ercc1^{+/-}$ mice ( $Ercc1^{+/-}$ 3m), 9-month-old $Ercc1^{+/-}$ mice ( $Ercc1^{+/-}$ 9m), and 20-month-old wild
90	type (WT 20m) C57 mice. <b>c</b> , Levels of 8-OHdG in spleens from $Ercc1^{+/-}$ 3m, $Ercc1^{+/-}$ 9m and
91	WT 20m mice (n=6 per group). <b>d</b> , Splenic weights normalized to body weight of $Ercc1^{+/2}$ 3m,
92	<i>Ercc1</i> <sup>+/-</sup> 9m and WT 20m mice (n=6 per group). <b>e</b> , Immunoblot detection of $\gamma$ H2AX in spleen,
93	heart, liver and lung from 10-month-old WT or 10-month-old $Ercc1^{+/-}$ ( $Ercc1^{+/-}$ ) mice. <b>f</b> ,
94	Representative images of H&E staining for 4N-MS1 tongue orthotopic transplant tumors. g, C57
95	mice were implanted with $5 \times 105$ 4N-MS1 cells into the tongue. Administration of different drug
96	treatments around the 7th day after 4N-MS1 implantation. Tumor growth curve showing the
97	tumor size after receiving Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group).
98	h, Multiplex bead-based protein analysis of lysate of mouse tongue tumor after receiving Isotype,
99	$\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 3 per group). <b>i</b> , Flow cytometry analysis of
100	$CD4^+$ Naïve T cells proportions in mouse tumors after receiving Isotype, $\alpha PD-1$ , $\alpha PD-1+CP$ or
101	$\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). <b>j</b> , Representative images and quantitative analysis of
102	P21 and CD62L staining in 4N-MS1 tongue orthotopic transplant tumors. (n= $\Box$ 6 per group). <b>k</b> ,
103	Tumor growth curves for MB49 and E0771 transplant models after receiving Isotype, $\alpha$ PD-1,
104	$\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). The statistical analysis was performed
105	using one-way ANOVA (c, d, h, j) and log-rank test (g, k). P values are shown, and error bars
106	indicate the mean $\pm$ SEM.



108Fig. 5 ATAC-Seq and RNA-Seq analyses of CD4+ naïve T cells provide evidence for the109potential of  $\alpha$ PD-1+DQ in the regulation of immunosenescence. a, Pattern diagram of cell110sorting, as well as combined sequencing with ATAC-Seq and RNA-Seq. b, Heatmap illustrating111differences in the expression levels of T cell di-related genes among different groups. c, DEGs112(Log<sub>2</sub>Foldchages > 0.5) of CD4 naïve T cells in tumors between  $\alpha$ PD-1 and DQ and isotype

113	groups enriched GO terms. d, ATAC-seq tracks showing the representative genes chromatin
114	accessibility in the Ccr7 and S100a11 loci for CD4 naïve T cells in mouse tumors from isotype,
115	$\alpha$ PD-1 and DQ, and $\alpha$ PD-1 groups. <b>e</b> , RNA-seq and ATAC-seq detected GO terms that were
116	simultaneously enriched in the $\alpha$ PD-1 and DQ and isotype groups. <b>f</b> , Expression of <i>Ccr7</i> , <i>Lck</i> ,
117	<i>Cfd</i> , <i>S100a11</i> , <i>p16</i> <sup><i>Ink4a</i></sup> , <i>p21</i> <sup><i>Cip1</i></sup> in CD4 <sup>+</sup> naïve T cells in mouse tumors after receiving Isotype,
118	$\alpha$ PD-1 or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). <b>g</b> , Flow cytometry analysis of CCR7 and
119	LCK in CD4 <sup>+</sup> Naïve T cells proportions in mouse tumors after receiving Isotype, $\alpha$ PD-1 or $\alpha$ PD-
120	1+DQ treatment (n= $\Box$ 6 per group). <b>h</b> , Representative images of CCR7 and LCK staining in 4N-
121	MS1 tongue orthotopic transplant tumors. The statistical analysis was performed using one-way
122	ANOVA ( <b>f</b> , <b>g</b> ). <i>P</i> values are shown, and error bars indicate the mean $\pm$ sem.



124	Fig. 6 The Phase II clinical trial COIS-01 validated the safety and efficacy of combining
125	senolytic drugs with anti-PD-1 therapy. a, Schematic representation of the clinical trial (COIS-
126	01) investigating the combination of ICIs with senolytics as neoadjuvant therapy for HNSCC. <b>b</b> ,
127	The waterfall chart displays the clinical characteristics of 24 patients in the COIS-01 trial. c,
128	Representative imaging, HE pathology, and intraoral photographs of two pCR patients from
129	COIS-01. MM represents the masseter muscle, MB represents the mandible, and the tumor area
130	is indicated by the circled region. Scale bar, 50 $\mu$ m. <b>d</b> , The radar chart shows the proportions of
131	various types of TRAEs in two clinical trials. e, Comparison of TRAEs between the COIS-01
132	and OOC-001 clinical trials. f, Representative images and quantifications of immunofluorescent
133	staining for CCR7 <sup>+</sup> Naïve T cells before and after treatment (n= $\Box$ 24 per group). The statistical
134	analysis was performed using t test (f). P values are shown, and error bars indicate the mean $\pm$
135	sem.
136	
137	



## 140 Extended Data Fig. 1 The trial design and outcomes of OOC-001.

a, Trial flow diagram. b, Representative pre- and post-treatment intraoral photographs, H&E 141 staining, and MRI images for MPR and noMPR patients. Scale bar =  $50 \mu m. c$ , The changes and 142 proportional statistics of TNM staging after treatment for lymph nodes in different patients. d. 143 Scatter plot depicts the pathological response and radiographic response of the primary tumor 144 after neoadjuvant treatment in the same patient (left), and the radiographic response of the 145 primary tumor and lymph node metastasis in the same patient after neoadjuvant treatment (right). 146 e. Pathological response of the primary tumor in patients treated with different cycles during 147 neoadjuvant therapy (left), radiographic response of the primary tumor in patients treated with 148 different cycles during neoadjuvant therapy (middle), and all remission include primary tumor 149 and lymph node metastasis in patients treated with different cycles during neoadjuvant therapy 150 151 (right). **f**, The rates of MPR for patients after 2 cycles, 3 cycles, and 4 cycles of treatment, as well as the rates of Grade 1-2 adverse events and Grade 3-4 adverse events. g, Survival curves for 152 patients in this clinical trial at the 24-month follow-up. h, Disease-free survival (DFS) and OS 153 154 curves for patients in this clinical trial at the 24-month follow-up.



## 157 Extended Data Fig. 2 Dynamic characterization of TCR landscape.

a, TCR-seq was performed on T cells from tumors (pre-treatment biopsy tumors), P0 (pre-158 treatment blood), and P1 (post-treatment blood) obtained from patients (from top to bottom, 159 patients SH1, SH2, SH3, SH4, SH5, SH6, SH7). The top 10 clonotype frequencies detected in T 160 161 cells that differed most in peripheral blood before and after treatment are shown in serial peripheral blood (left) and tumor tissue (right). **b**, From left to right represents changes in high 162 163 abundance clonotypes in tumors and blood before and after patient treatment, and patients from top to bottom are SH1, SH2, SH3, SH4, SH5, SH6, SH7. Each circle represents a clonotype. The 164 165 diameter of the circle indicates the concentration of the clonotype. Persistent clonotypes are marked as bright circles, with a single color representing one clonotype. For patients with MPR, 166 the predominant high-abundance clonotype present in tumors and blood before treatment 167 168 remained the predominant high-abundance clonotype after treatment. c, Pairwise similarity (Grantham distance) between the top 50 most common intratumoral TCR CDR3b clones. 169 Evaluate the similarity between the most common lengths of CDR3b amino acid sequences in 170 171 each patient (from top to bottom, patients SH1, SH2, SH3, SH4, SH5, SH6, SH7). Red indicates 172 the most expanded clone. **d**, Bar plot of TCR and BCR clonotypes across all T cells and B cells in MPR or noMPR groups from P0, P1 and tumors. One clonotype consists strictly of one paired 173  $\alpha$ -/ $\beta$ -chain V(D)J TCR. e. Pie chart of the antigen specificity of detected TCRs when considering 174  $\alpha$ -,  $\beta$ -, and paired strands. CMV, cytomegalovirus; EBV, Epstein-Barr virus; InfluenzaA, 175 176 influenza A virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; HS, Homo 177 sapiens antigen; HIV-1, human immunodeficiency virus 1; HCV, hepatitis C virus; YFV, yellow fever virus; DEV, dengue virus. f, Representative immunofluorescence images of senescent 178 179 markers P16 and P21 on paraffin sections from MPR and noMPR patients in two patient cohorts (Cohort1 n=50, Cohort2 n=61). 180



# 183 **Extended Data Fig. 3 Development and validation of IAGs.**

a, Human immune cell samples from multiple data sets were used for single-cell RNA 184 sequencing analysis to construct the IAGs. **b**, The IAGs significantly enriched in B cells (middle) 185 and T cells (right) in peripheral blood of frail elderly people (GSE157007). c, The IAGs is 186 significantly enriched in B cells (middle) and T cells (right) in the peripheral blood of elderly 187 women (PRJCA002856). d, The IAGs is significantly enriched in all immune cells in bone 188 marrow of older women (GSE141595). e, Violin plot of expression of the different all cells IAGs 189 score in HNSCC tumors between MPR and noMPR groups (left), and in TNBC tumors between 190 PR and SD groups (right). Black lines with different lengths indicate which two groups were 191 192 compared. Wilcoxon signed-rank test.



#### 194 Extended Data Fig. 4 Anti-tumor reactivity and immunosenescence features of T cell

#### subtypes. 195

a, Violin plot of expression of all T cells IAGs score in HNSCC tumors between MPR and 196 noMPR groups. Black lines with different lengths indicate which two groups were compared. 197 Wilcoxon signed-rank test. **b**, Gene Venn diagram of differential genes of T cell subtypes in 198 tumors between MPR and noMPR groups. c, UMAP shows the distribution of T cell and B cell 199 subtypes in TNBC. d, Box plot of the percentage of the T cell clusters in TNBC tumors between 200 PR and SD groups. The boxed plot on the left of each T cell cluster is the PR group, and on the 201 202 right is SD group. Box middle lines, median; box limits, upper and lower quartiles. Black lines 203 with different lengths indicate which two groups were compared. Wilcoxon signed-rank test. e, Violin plot of expression of all T cells IAGs score in TNBC tumors between PR and SD groups. 204 205 Black lines with different lengths indicate which two groups were compared. Wilcoxon signedrank test. f, The Ridge plot of IAGs score analysis for T cells clusters in TNBC. g, Dot plot of 206 intersection genes of TNBC T cell DEGs and IAGs between PR and SD groups. h, DEGs 207 (Log2Foldchages > 0.5) of CCR7<sup>+</sup> CD4 naïve T cells and CXCL13 CD4 T helper cells between 208 MPR and noMPR enriched GO terms in tumors. Log-rank test (two-sided).  $*P \square < \square 0.05$ , 209 \*\*P□<□0.01, \*\*\*P□<□0.001. 210



# **Extended Data Fig. 5 CD4 T cell differentiation pathway.**

214	<b>a</b> , Frequency of V $\alpha/\beta$ gene usage among CCR7 <sup>+</sup> CD4 T cells and FOXP3 <sup>+</sup> CD4 Treg cells in
215	tumors and CCR7 <sup>+</sup> CD4 T cells in blood (V genes ordered by decreasing frequency in CCR7 <sup>+</sup>
216	CD4 T cells in blood). b, UMAP embedded CD4 T cell trajectory with mapping of pseudotime
217	(top left), cell subtype distribution (top right), single-cell transcriptional profiles of each tissue
218	(bottom left), and different groups (bottom right) sampled in the study. c, Pseudotime
219	distribution diagram of the proportion of CD4 T cells in tumors, the MPR group on the left, the
220	noMPR group on the right. d, Differential genes of CD4 Naïve T cells in tumors and peripheral
221	blood.



% 0 MPR noMPR

# 223 Extended Data Fig. 6 Immunosenescence features of B cells.

224	a, Paired BCR results Shows the overall number of BCR clones (upper row), and the status of
225	single clones after normalization (lower row). b, Gene Venn diagram of differential genes of B
226	cell subtypes in tumors between MPR and noMPR groups. c, Dot plot of intersection genes of
227	HNSCC B cell DEGs and IAGs between MPR and noMPR groups (upper), and between PR and
228	SD groups in TNBC. <b>d</b> , The dot plot showing DEGs (Log2Foldchages $> 0.5$ ) of B cells between
229	MPR and noMPR groups enriched GO terms in tumors. e, GO terms enriched in CD27 <sup>-</sup> Memory
230	B cells in tumors between MPR and noMPR groups. adjusted p value $< 0.05$ . f, Heatmap
231	showing the expression of ligand-receptor pairs highly expressed in T cell subtypes and B cell
232	subtypes in tumor. g, Immunohistological staining quantifications of CD27 and S100A11 in
233	HNSCC patients of two cohorts (MPR n=12, noMPR n=14).



## 235 Extended Data Fig. 7 Dynamics of myeloid cell subtypes after neoadjuvant

## chemoimmunotherapy.

a, UMAP embedding myeloid cell trajectory with mapping of pseudotime. b, UMAP plots 237 showing the distributions myeloid cells between MPR and noMPR groups. c. The proportion of 238 myeloid cells in different tissues. **d**, Gene similarity between  $IGF1^+$  M $\phi$  and myeloid cell 239 clusters from peripheral blood. e, UMAP showing the distribution of myeloid cell clusters (left), 240 embedding the single-cell transcriptional profiles of myeloid cell from each tissue sampled (top 241 right), and from different groups (bottom right) in TNBC. f, The cellular compositions of 242 myeloid cell clusters in tumors and peripheral blood between PR and SD groups in TNBC. g. 243 Violin plot of six key SASP expression of the IAGs score in myeloid cell clusters in tumors (left) 244 and peripheral blood (right). h, Violin plot of six key SASP expression of the IAGs score in 245 246 myeloid cell clusters in tumors (left) and peripheral blood (right) from TNBC. i, Low expressions of  $IGF1^+$  M $\phi$  signature gene were significant associated with better OS and DFS. 247 Log-rank test (two-sided). 248



# 251 Extended Data Fig. 8 The effect of Senolytics combined with αPD-1 on TIME of 4-NQO

# 252 mice.

253	a, Representative images of tongue sections from mice, fed with 4-nitroquinoline-1-oxide (4-
254	NQO)-containing drinking water for 12, 20, and 28 weeks, stained with hematoxylin and eosin
255	(HE). Scale bar, 50 $\mu$ m. <b>b</b> , Images of tongue of mice after receiving Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP
256	or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 each group). Red arrows indicate tumor-like nodules. <b>c</b> , Line
257	graph illustrating the change in mouse body weight over time after receiving Isotype, $\alpha$ PD-1,
258	$\alpha$ PD-1+CP or $\alpha$ PD-1+DQ treatment (n= $\Box$ 6 per group). <b>d</b> , Flow cytometry gating strategy for
259	assessing the proportions of CD4 <sup>+</sup> , CD8 <sup>+</sup> , as well as T cell subtypes. e-g, Flow cytometry
260	immunophenotyping of splenic cells, bone marrow Cells and blood showing the frequencies of
261	CD4 <sup>+</sup> , CD8 <sup>+</sup> and B220 <sup>+</sup> cells in mice after receiving Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ
262	treatment (n= $\Box$ 6 each group). <b>h</b> , Senescence markers <i>p</i> 16 and <i>p</i> 21 expression in CD8 <sup>+</sup> TILs from
263	the mice treated with Isotype, $\alpha$ PD-1, $\alpha$ PD-1+CP or $\alpha$ PD-1+DQ (n=6 per group).







DAPI PAN-CK P21 CD62L




medRxiv preprint doi: https://doi.org/10.1101/2024.10.14.24315428; this version posted October 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## 265 Extended Data Fig. 9 αPD-1+DQ enhanced the anti-tumor effect in breast and bladder

## 266 cancer xenograft models.

a-b, The whole-exome sequencing (WES) of 4N-MS1 cells reveals the classification of Single 267 Nucleotide Variants (SNV Class) and the top 10 genes with the highest mutation frequencies. c. 268 Tumor images and survival curves for the MB49 transplant model after receiving Isotype, αPD-1, 269  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per group). **d**, The survival curves for the E0771 270 transplant model after receiving Isotype,  $\alpha$ PD-1,  $\alpha$ PD-1+CP or  $\alpha$ PD-1+DQ treatment (n=6 per 271 group). e-f, Representative immunofluorescence images and statistical analysis of the senescent 272 273 marker P21 and the Naïve cell marker CD62L in MB49 and E0771 tumor xenografts after receiving Isotype, aPD-1, aPD-1+CP or aPD-1+DQ treatment (n=5 per group). 274

medRxiv preprint doi: https://doi.org/10.1101/2024.10.14.24315428; this version posted October 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: https://doi.org/10.1101/2024.10.14.24315428; this version posted October 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## **Extended Data Fig. 10 Transcriptomic and epigenetic dynamics of CD4 naive T cells**

## **following the αPD-1+DQ therapy.**

**a**, Volcano plot of differentially expressed genes between  $\alpha$ PD-1+DQ and Isotype groups (left), 278  $\alpha$ PD-1 and Isotype groups (middle),  $\alpha$ PD-1+DO and  $\alpha$ PD-1 groups (right). **b**, DEGs 279 (Log2Foldchanges > 0.5) of CD4 naïve T cells in tumors between  $\alpha$ PD-1 and Isotype groups 280 enriched GO terms. c, Proportions of the ATAC-seq peak regions representing various genome 281 annotations identified in Isotype,  $\alpha$ PD-1+DO and  $\alpha$ PD-1 groups. **d**. The heatmap of different 282 annotated genes in Isotype, aPD-1 and aPD-1+DO groups from ATAC-seq. e, Venn diagram of 283 peaks of CD4 naïve T cells in Isotype,  $\alpha$ PD-1 and  $\alpha$ PD-1+DO groups. **f**, ATAC-seq tracks 284 showing the representative genes chromatin accessibility in the Lck, Cfd, and Slfn2 loci for CD4 285 naïve T cells in Isotype, αPD-1+DQ and anti-PD-1 groups. g, RNA-seq and ATAC-seq detected 286 287 GO terms that were simultaneously enriched in the  $\alpha$ PD-1 group and Isotype group (left) and GO terms that were enriched in open chromatin regions unique to the  $\alpha$ PD-1+DO group and  $\alpha$ PD-288 1group (right). 289

290